Structure guided lead generation toward nonchiral M. tuberculosis thymidylate kinase inhibitors by Song, Lijun et al.
Structure Guided Lead Generation toward Nonchiral M. tuberculosis
Thymidylate Kinase Inhibitors
Lijun Song,† Romain Merceron,‡,§ Begoña Gracia,∥,◆ Ainhoa Lucía Quintana,∥,◆
Martijn D. P. Risseeuw,† Fabian Hulpia,† Paul Cos,⊥ Jose ́ A. Aínsa,∥,◆ Heĺeǹe Munier-Lehmann,#,○
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ABSTRACT: In recent years, thymidylate kinase (TMPK), an enzyme indispensable for bacterial DNA biosynthesis, has been
pursued for the development of new antibacterial agents including against Mycobacterium tuberculosis, the causative agent for the
widespread infectious disease tuberculosis (TB). In response to a growing need for more eﬀective anti-TB drugs, we have built
upon our previous eﬀorts toward the exploration of novel and potent Mycobacterium tuberculosis TMPK (MtTMPK) inhibitors,
and reported here the design of a novel series of non-nucleoside inhibitors of MtTMPK. The inhibitors display hitherto
unexplored interactions in the active site of MtTMPK, oﬀering new insights into structure−activity relationships. To investigate
the discrepancy between enzyme inhibitory activity and the whole-cell activity, experiments with eﬄux pump inhibitors and eﬄux
pump knockout mutants were performed. The minimum inhibitory concentrations of particular inhibitors increased signiﬁcantly
when determined for the eﬄux pump mmr knockout mutant, which partly explains the observed dissonance.
■ INTRODUCTION
Tuberculosis (TB) has been ranked as the most fatal infectious
disease worldwide and constitutes the leading cause of death
among people with HIV/AIDS.1 As one of the most ancient
human infectious diseases, it revives with immigration,
increased homelessness, and the emergence of HIV/AIDS. It
declines with improved public health practices, the develop-
ment of and access to antituberculosis drugs and antibiotics,
and immunization with M. bovis BCG vaccine.2−4 At the early
stage of TB infection, people with a low immunity directly
develop the active disease, which is called primary or primary-
progressive TB. Most people, however, progress into
asymptomatic disease, which is referred to as latent tuber-
culosis.5 On the basis of the tuberculin skin test reactivity, it is
estimated that one-third of the world’s population is infected
with latent TB, which may be activated upon aging,
malnutrition, treatment with immunosuppressive agents, HIV
coinfection, etc.1 It is estimated that 10.4 million new TB cases
occurred in 2015.1 South-East Asian and Western Paciﬁc
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regions accounted for 58% of these cases, Africa for 28%, while
about 3% of the cases were allocated in high-income countries.1
The currently used regime for drug-susceptible TB consists of
four ﬁrst-line drugs to be taken almost daily for six months or
longer: isoniazid, rifampicin, ethambutol, and pyrazinamide.
This lengthy treatment period with an associated risk of poor
patient compliance increases the risk of drug-susceptible TB to
develop into multidrug-resistant TB (MDR-TB) and exten-
sively drug-resistant TB (XDR-TB).6,7 Treatment of MDR-TB
and XDR-TB is much longer, more expensive, less eﬀective, and
causes more severe side eﬀects than that for drug-susceptible
TB. Although the new anti-TB drugs bedaquiline and
delamanid have been recommended for the treatment of
MDR-TB by WHO, resistant isolates were reported as early as
2014.8,9 Therefore, there is a pressing need to develop novel
anti-TB drugs that allow shortening of the treatment period.
Drugs exerting their eﬀect via novel mechanisms of action are
preferred, as they are believed to be less susceptible to generate
cross-resistance with already existing antituberculosis drugs and,
hence, could be useful for treating MDR-TB and XDR-TB.10
Human TB is caused by Mycobacterium tuberculosis (Mtb).8
The intrinsic resistance of Mtb to common antibiotics is due to
the combination of several factors, including a highly lipid-rich
cell wall that forms a permeability barrier, and the activity of
eﬄux pumps that transport noxious agents out of the cell.11−14
Moreover, Mtb manages to survive inside macrophages (the
ﬁrst-line bodyguard of the human immune system) and hides
itself by building granulomas inside the deep lung tissue (latent
TB). Once the host immune system is weakened, the bacterium
starts replicating and invading the neighboring tissue of the
lung.11,15,16 The granuloma creates heterogeneous micro-
environments including a diﬀerent blood supply, diverse pH,
and various extent of caseum.17,18 As a result, it is challenging
for anti-TB drugs to reach and kill all bacilli.19
Mtb thymidylate kinase (MtTMPK), a key enzyme for the
synthesis of thymidine triphosphate as a DNA building block, is
essential for the survival of Mtb.20 Its known crystal structure
and druggable active site make it an attractive target for drug
design.21−23 In this paper, we describe our attempts to optimize
the MtTMPK inhibitory activity of the earlier identiﬁed non-
nucleoside hit 1 via scaﬀold screening, ligand eﬃciency
exploration, and structure-based drug design.24
The envisioned modiﬁcations were inspired by the cocrystal
structure of MtTMPK in complex with 1 (cf. infra), indicating
that the thymine ring (ring A) forms a primary binding motif
with the enzyme that is very similar to that observed in the
crystal structures of substrate-like ligands,20 including a π−π
stacking interaction with Phe70 and hydrogen bonds between
O4 and N3 and Arg74 and Asn100, respectively. Rings B, C, and
D, however, mainly formed hydrophobic interactions with the
enzyme. Therefore, we decided to investigate if the meta-
piperidine ring (ring B) could be substituted by either a para-
piperidine (2), an azetidine (7), or an aminoalkyl moiety (11
and 12). We also explored variations in the inter-ring space by
adding a methylene unit (analogues 3, 8, and 9) or a carbonyl
group (analogue 13) between rings B and C or a methylene
group between A and B (analogue 5). We also investigated the
eﬀect of moving the terminal phenoxy ring from the meta- to
the para-position (as in 4, 6, 10, and 14). Next, we tried to
optimize the ligand eﬃciency by removing the distal D-ring,
while replacing the ring C with diﬀerent hetero(aryl) moieties
or a cyclohexyl group (analogues 15−41). Quinolin-2-yle
analogue 35, which resulted from this eﬀort, was further
optimized to aﬀord a potent MtTMPK inhibitor with a new
chemotype (analogues 42−44).
■ RESULTS AND DISCUSSION
Synthesis. Generally, the synthesis of the envisioned
analogues comprised reductive amination of an azaheterocyclic
or aminoalkyl N3-BOM-protected thymine derivative with an
appropriate aldehyde. Final acidic cleavage of the BOM-group
aﬀorded the desired ﬁnal compounds. The azaheterocyclic
(substituted azetidine or piperidine) and aminoalkyl thymine
intermediates were prepared via alkylation of thymine with the
appropriate mesylates.24
Scheme 1. Synthesis of the Required Aldehyde Building Blocksa
aReagents and conditions: (a) MeOH, cat. H2SO4, 0 °C to reﬂux, overnight; (b) (i) MeOH, cat. H2SO4, 0 °C to reﬂux, overnight; (ii) H2, Pd/C,
AcOEt, rt, 2 h; (c) Cu(OAc)2, molecular sieves, pyridine, rt, overnight; (d) (i) LiAlH4, dry THF, 0 °C to rt, 20 min; (ii) Dess−Martin reagent,
CH2Cl2, 0 °C to rt, 8 h; (e) Cs2CO3, N,N-dimethylglycine·HCl, CuI, dry 1,4-dioxane, 90 °C, 24 h; (f) SeO2, 1,4-dioxane, 100 °C, 1.5−2 h.
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When the required aldehydes were not commercially
available, they were prepared as described in Scheme 1. The
preparation of aldehyde 50 started with Fischer esteriﬁcation of
3-hydroxyphenylacetic acid 45. Chan−Lam coupling with
phenylboronic acid and reduction of the resulting product 49
with LiAlH4 and subsequent reoxidation with Dess−Martin
furnished the desired aldehyde 50. Esteriﬁcation of m-coumaric
acid 47, followed by catalytic hydrogenation, yielded propionic
ester 48, which was converted to the required aldehyde 52 via
an analogous method. The synthesis of aldehyde 55 was ﬁrst
attempted via Chan−Lam and Ullmann coupling using 2-
methylquinolin-4-ol, with either phenylboronic acid or
iodobenzene, but both reactions failed to give the desired
product. The failure in the Ullmann coupling might be due to
the poor solubility of 2-methylquinolin-4-ol, as well as the low
nucleophilic character of the quinolone compared to a phenol.
However, Ullmann coupling between 4-chloro-2-methylquino-
line 53 and phenol generated the substituted phenoxyquinoline
54, which upon oxidation with selenium dioxide aﬀorded
aldehyde 55. Aldehydes 57 and 60 were synthesized using
similar conditions.
Compounds 2−12 were synthesized as depicted in Scheme
2. The ﬁnal TFA catalyzed deprotection step24 was found to
produce the desired products in varying yields. Puriﬁcation of
the ﬁnal compounds was complicated by the presence of
undesired side products with a molecular mass of 2 M + 12. (M
represents the exact mass of the deprotected substrates.)
Attempts to optimize this deprotection step by lowering the
temperature or diminishing the TFA concentration failed. 2D-
NMR analysis allowed us to identify the main side product as
dimer 73, which is probably formed by a double electrophilic
aromatic substitution reaction of formaldehyde released during
the deprotection reaction.25 To circumvent this problem, we
explored the use of cysteine as a formaldehyde scavenger.26 By
using a 0.25 M solution of L-cysteine·HCl in 80% TFA/H2O,
little to no byproduct formation was observed.
The method to access amides 13 and 14 was similar as
described earlier for the meta-analogues (Scheme 3).24
Enzymatic Evaluation and Structural Analysis. At the
onset of this study, we sought to obtain structural information
about the possible binding mode of inhibitor 1 into MtTMPK
in order to fuel further inhibitor development. To this end, we
Scheme 2. Synthesis of Azetidinyl, para-Piperidinyl, and Aminoalkyl Analogues and the Structure of Compound 73a
aReagents and conditions: (a) (i) K2CO3, dry DMF, 80 °C, 3 h (71), overnight (65), 48 h (67 and 69), 4 days (63); (ii) 10% TFA/CH2Cl2, 2−4 h,
rt; (b) (i) substituted aromatic aldehydes, NaBH(OAc)3, dry 1,2-dichloroethane, rt, overnight; (ii) method 1 TFA, 72 °C, 30 min to 1 h; method 2
80% TFA/H2O, 0.25−0.27 M cysteine, 72 °C, 3−12 h; (c) (i) (Boc)2O, Et3N, CH2Cl2, rt, 2 h; (ii) MsCl, Et3N, dry dichloromethane, 0 °C, 1 h.
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determined the cocrystal structure of MtTMPK in complex
with 1 at 2.85 Å resolution (PDB code: 5NQ5), which reveals
the key interaction features. Consistent with its competitive
mode of inhibition against the natural substrate dTMP,
compound 1 is bound with a high occupancy in the active
site of MtTMPK (Figure 1).
Compound 1 adopts a surprising bent conformation that
places rings A and B into the active site pocket and rings C and
D protruding outward at a right angle (Figure 1A). The
thymidine ring (ring A) reaches deep into the catalytic pocket
where it is stabilized via hydrophobic interactions between its 5-
methyl group and Arg95, Pro37, and Phe36 side chains (Figure
1A and 1B). By analogy to the interactions of thymidine-like
TMPK inhibitors,20 compound 1 also displays π−π electron
stacking interactions between ring A and Phe70 and additional
anchoring via hydrogen bonds linking the O4 and N3 groups of
the thymine ring with Arg74 and Asn100, respectively (Figure
1A and 1B).
The meta-piperidine ring (ring B) adopting a chair
conformation, protrudes out of the active site and positions
as the deoxyribose ring of dTMP would to establish a π-alkyl
interaction with the aromatic side chain of Tyr103 (Figure 1C
and 1D) Of interest, the phenyl ring (ring C) unexpectedly
bends away from the substrate channel and binds into a newly
formed hydrophobic pocket establishing a CH-π electron
interaction with Phe70. Binding of the inhibitor is possible
through a displacement of the α-helix (α2) bearing Leu52, and
this residue adopts a new rotameric conformation to enable
hydrophobic interactions between the phenyl ring and
neighboring hydrophobic side chains of Ala48, Ala49, and
Leu52. The S-enantiomer, which was shown to be a more
potent inhibitor than the R-enantiomer, provides the correct
geometry for the ligand to adopt this bent conformation.24 The
diphenyl ether group is further anchored through ring D, which
occupies a new binding pocket obtained after the reorientation
of the Arg107 side chain and is sandwiched between residues
Met66 and Arg107 establishing a cation-π interaction with the
guanidinium group of Arg107.
Next our eﬀorts were directed toward the identiﬁcation of
MtTMPK inhibitors with new chemotypes, to increase chances
of identifying analogues with whole-cell activity. First we
focused on altering ring B, i.e., the meta-substituted piperidine
ring (Figure 2).
Regioisomer 2, obtained by repositioning the thymine ring of
1 from the meta- to the para-position of the piperidine ring,
displayed a slightly better MtTMPK inhibitory activity than
compound 1. This result is encouraging since compound 2
possesses internal symmetry and is consequently easier to
prepare. Moving the terminal phenoxy ring of 2 to the para-
position of ring C (compound 4) increases the IC50 by a factor
5. Homologation of the linker between the B- and C-ring
aﬀorded compound 3, which exhibited a marginally decreased
inhibitory activity, while adding a methylene between the
thymine and piperidine rings led to inactive derivatives 5 and 6.
Replacement of the piperidine by an azetidin-3-yl ring, as in 7−
10, generally led to a dramatic drop in inhibitory potency.
Compound 11, which could be considered as a ring opened
form of the meta-piperidine analogue 1, gave a 7-fold drop in
the IC50 value, while compound 12, an acyclic variant of the
para-piperidine analogue 2, was drastically impaired in its
inhibitory potency.
Changing the methylene group between rings B and C of
inhibitors 2 and 4 by a carbonyl group to produce more rigid
Scheme 3. Synthesis of Amide-Containing para-
Piperidinylthymine Analoguesa
aReagents and conditions: (a) (i) EDC, 4-DMAP, dry CH2Cl2,
overnight; (ii) H2, Pd/C, EtOH, 6 h, rt; (iii) THF/H2O, rt, 4 h.
Figure 1. Structural characterization of the binding mode of
compound 1 and overlay of compound 1 binding pose with dTMP
in the active site of MtTMPK. (A) Cocrystal structure of compound 1
bound to MtTMPK at 2.85 Å resolution. Protein is shown in a pale
yellow cartoon representation. Compound 1 (stick representation,
carbon atoms in white) and the side chains of MtTMPK interacting
residues (stick representation, carbon atoms in orange) are depicted.
The corresponding unbiased Fo-Fc diﬀerence electron density
(contoured to +3 sigma) calculated before adding the ligand in the
reﬁnement process is shown as a green mesh. (B) Schematic drawing
of compound 1 binding site displaying key MtTMPK interacting
residues. (Hydrogen bonds are represented with a red dashed line.)
Compound 1 comprises four rings named A−D. (C) Cocrystal
structure of MtTMPK in complex with compound 1 showing the
binding of the inhibitor (stick representation, carbon atoms in white)
in the MtTMPK active site. Protein is depicted in a pale yellow cartoon
representation. Crystallographic pose of dTMP (stick representation,
carbon atoms in cyan) in MtTMPK (PDB code 1G3U) has been
overlaid with compound 1 cocrystal structure for comparison. The
superimposition shows a strict conservation of the thymidine core
position. (D) Schematic drawing of dTMP binding site displaying key
MtTMPK interacting residues. (Hydrogen bonds are represented with
a red dashed line.)
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amides 13 and 14 was also at the expense of the inhibitory
potency.
In an attempt to identify MtTMPK inhibitors with an
improved ligand eﬃciency (LE), we decided to synthesize
truncated analogues of the para-substituted piperidine analogue
2 in which the D-ring was omitted and in which we explored
alternative C-rings (Figure 3). From this exercise, we deduce
that deletion of the terminal phenoxy group decreases the
inhibitory potency with a factor 22 (compound 15). As shown
in Figure 3, a planar C-ring is necessary for the enzyme potency
(pairs 15/32); however, big aryl rings with improved inhibitory
potencies do not yield a better ligand eﬃciency (pairs 15/34,
29/41). Branching the methylene between rings B and C had
no inﬂuence on the activity (pairs 15/31).27 We observed that
the inhibitory potency beneﬁts from the introduction of
electron-withdrawing substituents on the C-ring (analogues
20−22/15). Consistently, electron-poor heterocycles are also
favorable (e.g., analogues 27 and 35). Comparing with other
modiﬁcations, these electron-deﬁcient substituents also gen-
erated active analogues with a high LE value (0.25−0.29), out
of which compound 21 emerged as the best.
Using the cocrystal structure of MtTMPK in complex with 1,
modeling studies indicated that introducing a carboxylic acid
functionality at C-3 of ring C (28) could aﬀord a beneﬁcial
electrostatic interaction with Arg107. As shown in Figure 4, the
position of Arg107 in the model points to the carbonyl group of
ring A instead of the expected carboxylic group of ring C,
compared to the position obtained from the cocrystal structure.
Analogues that have a similar group or an isosteric tetrazole
ring at the C-4 position were also tried (23 and 24). However,
the introduction of these acidic substituents tends to lower the
inhibitory potency and LE (0.20−0.21). This might be due to
conformational changes of the active site, which are induced by
the carboxylic group and lead to weaker binding.
Since the eﬀect of all of the truncated analogues described in
Figure 3 were found to be vastly inferior to 2, ring D is deemed
necessary for good MtTMPK inhibition. Taking into account
the synthetic feasibility and the fact that quinolines and
quinolones have emerged as promising scaﬀolds for developing
antimycobacterial agents,28 quinoline derivative 35, which has a
favorable LE of 0.27, was selected for further structural
elaboration.
An overlay of the docking poses of compounds 2 and 35 in
MtTMPK is represented in Figure 5A. As expected, the
thymine and piperidine moieties of 2 and 35 occupy similar
positions. The aromatic tails of 2, however, point toward an
additional pocket in the enzyme. This led us to explore if this
additional pocket could be occupied by introducing a phenoxy
group at position 4 of the quinolone moiety of 35. The
structures of the envisaged 4-phenoxyquinoline derivatives are
shown in Figure 5B. Indeed, compound 42 shows a 5-fold
improved MtTMPK inhibitory potency compared to analogue
2 and an 8-fold improvement compared to the parent quinoline
35. Introduction of a chlorine substituent at two diﬀerent
Figure 2. MtTMPK inhibitory activities of the analogues with alternative scaﬀolds for the meta-substituted B-ring of compound 1.
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positions of 42 aﬀorded analogues 43 and 44, of which 43
represents the most potent MtTMPK inhibitor identiﬁed so far,
bearing this particular scaﬀold.
The cocrystal structure of MtTMPK in complex with
compound 43 at 2.35 Å resolution (PDB code: 5NR7) reveals
the key interaction features involved in binding of compound
43 to the enzyme and is consistent with the predicted binding
conﬁguration obtained from the docking experiments. Inhibitor
43, which is bound in the active site of the enzyme, was placed
in the residual Fobs-Fcalc electron density and adopts an L
shaped conformation (Figure 6).
Consistently with the cocrystal structure of 1-MtTMPK, ring
A adopts an identical pose to that observed in the crystal
structures of substrate-like ligands. The para-substituted
piperidine ring (ring B) establishes a similar π-alkyl interaction
with Tyr103 as observed in the cocrystal structure of 1 but
displays a slightly diﬀerent binding pose. Interestingly, the
quinoline aromatic group protrudes linearly to ring B out of the
catalytic pocket and is located in a new binding spot
establishing a π-alkyl interaction with Leu52 and an edge-to-
face π-stacking interaction with His53. Despite the weak ligand
electron density, which does not completely support the
positioning of ring D in the model, the ether group can be
placed with conﬁdence supporting the orientation of ring D
that bends in an opposite direction than the one observed for 1.
The chlorobenzene ring is involved in hydrophobic interactions
with Ala49 and could establish a parallel-displaced π-stacking
interaction with Tyr39.
Antimicrobial Activity and Enzymatic Inhibitory
Activity. Next to their ability to inhibit MtTMPK, all ﬁnal
compounds were tested for M. tuberculosis growth inhibitory
activity. The antimycobacterial activity of meta-piperidinylth-
ymine 1 reported in a previous study turned out to be
nonrepeatable (IC50 > 64 μM, H37Ra),
24,29 but we found that
analogue 42 had a 4-fold stronger antituberculosis activity than
compound 1 (H37Rv, Table 1). This result is in line with the
enzymatic inhibitory activity, which is 8-fold higher for 42
compared to 1. Analogue 43 is 33-fold more potent than
derivative 42, which represents the most potent compound in
this study so far (H37Ra). All analogues did not display severe
cytotoxicity, with only 42 and 43 having some cytotoxicity
against MRC-5 ﬁbroblasts. The analogues not included in
Table 1 were found to have no antibacterial activity for the
H37Ra strain up to 64 μM.
We hypothesized that the discrepancy between the potent
enzyme inhibitory activity and the whole-cell antimycobacterial
Figure 3. SAR and LE exploration of ring C based on para-piperidinylthymine 2.
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activity could be due to poor mycobacterial uptake or due to
eﬄux.
To explore this hypothesis, the MIC of the selected
analogues was determined ﬁrst in the presence of eﬄux
pump inhibitors (at one-fourth of their MIC) and, second, by
using a series of M. tuberculosis mutants defective in the
production of eﬄux pumps, along with the wild type strain
H37Rv. From Table 2, it can be observed that in the presence
of the eﬄux inhibitor verapamil, a calcium channel blocker, the
MIC of two compounds (21 and 35) markedly decreased in
comparison to that for the reference strain H37Rv. In addition,
the M. tuberculosis mutant defective in the Mmr eﬄux pump
also showed a signiﬁcant (more than 4-fold change) decrease in
the MICs of these two analogues. These results strongly suggest
that active eﬄux plays an important role in the transport of
compounds 21 and 35, so this could be the reason for the
discrepancy between antituberculosis activity and enzyme
inhibitory activity. For compounds 1, 42, and 43, the decrease
in the MICs in the presence of eﬄux inhibitors is moderate,
and no signiﬁcant change could be detected in the eﬄux
defective mutants. We can conclude that in these cases eﬄux
may play a moderate role in the resistance to these compounds,
and in any case, this would not be mediated by Tap or Mmr
eﬄux pumps. Finally, we could not detect any eﬀect of either
addition of eﬄux inhibitors or deletion of gene encoding eﬄux
pumps for compound 24, indicating that this compound may
have retarded uptake due to its negative charged tetrazole ring.
■ CONCLUSION
Starting from the previously identiﬁed hit 1, scaﬀold screening
and ligand eﬃciency exploration resulted in two novel chemical
series: one series represented by the phenoxylbenzyl analogue 2
and a truncated series represented by quinolin-2-yl analogue 35.
Structure-guided scaﬀold morphing between compound 2 and
35 furnished phenoxylquinolin-2-yl derivatives with a potent
MtTMPK inhibitory activity and improved antibacterial activity.
A potential explanation for the observed discrepancy between
IC50 and MIC values is provided by assessing the
antimycobacterial activity in the presence of eﬄux pump
inhibitors or by using mutant M. tuberculosis strains deﬁcient in
eﬄux pumps. In particular, the cellular activity of 35 was
potentiated 128-fold when tested on the mmr eﬄux pump
knockout strain. These observations provide possible directions
for further inhibitor development, e.g., by combining the
optimized MtTMPK inhibitors with an eﬄux pump inhibitor,
by designing hybrid compounds that feature both an MtTMPK
as well as an eﬄux pump inhibitor motif, or, ideally, by looking
for MtTMPK inhibitors that feature structural motifs that
facilitate mycobacterial uptake.
■ EXPERIMENTAL SECTION
Expression and Puriﬁcation of Mycobacterium tuberculosis
Thymidylate Kinase (MtTMPK). MtTMPK was expressed and
puriﬁed as previously described with minor modiﬁcations.21 In short,
the pHL50 vector containing the coding sequence of wild-type
MtTMPK was used to transform E. coli BLi5 competent cells.
Transformed cells were selected on LB agar plates containing 100 μg/
mL of carbenicillin and 34 μg/mL of chloramphenicol and directly
Figure 4. Structure overlay of compound 1 (stick representation,
carbon atoms in white) and docking pose of compound 28 (carbon
atoms in cyan) in the MtTMPK active site. Protein is shown in a pale
yellow cartoon representation. Key MtTMPK interacting residues
(stick representation, carbon atoms in orange) with compound 1 are
shown: in particular, Arg107 is in close proximity to the ether bridge
between rings C and D. For compound 28, the envisaged favorable
electrostatic interaction is shown in a red dashed line between the
carboxyl moiety and Arg107 (in stick representation, carbon atoms in
cyan) in the docked structure.
Figure 5. Docking poses of compounds 2 and 35 in the MtTMPK active site. (A) Structural overlay of inhibitors 2 (in stick representation, carbon
atoms in white) and 35 (in stick representation, carbon atoms in gray) docked poses in the MtTMPK catalytic pocket. Protein is depicted in a pale
yellow cartoon representation. Key interacting residues are represented in stick conformation and colored in orange for carbon atoms. (B) Design of
the phenoxyl quinoline series and their corresponding inhibition constants.
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used to inoculate 1 L of 2XYT medium supplemented with antibiotics.
The cells were allowed to grow at 37 °C, and protein production was
induced with 1 mM isopropyl-1-thio-β-D-thiogalactoside when the
culture reached an absorbance of 1.5 at 600 nm. After 3 h of
incubation at 37 °C, cells were harvested by centrifugation at 8000g at
4 °C and stored at −80 °C before proceeding with puriﬁcation. Cells
from 1 L of culture were resuspended in 50 mL of cold lysis buﬀer
containing 50 mM Tris HCl pH 8.0 supplemented with an
antiprotease cocktail (Roche) and disrupted by sonication. After
centrifugation at 20000g for 30 min at 4 °C, the ﬁltered bacterial lysate
was injected on a 5 mL Blue-Sepharose column pre-equilibrated with
lysis buﬀer. The column was washed with lysis buﬀer and most of the
protein was eluted with elution buﬀer containing 50 mM Tris HCl pH
8.0, 1 M NaCl. A second elution was performed using elution buﬀer
containing 50 mM Tris HCl pH 8.0, 2 M NaCl. Fractions containing
MtTMPK were pooled and injected on a HiLoad Superdex 75 16/600
column equilibrated with 20 mM Tris HCl pH 7.4, 1 mM EDTA as
polishing and desalting steps. MtTMPK fractions were pooled and
Tris(2-carboxyethyl)-phosphine (TCEP) was added to 1 mM ﬁnal
concentration before ﬂash-freezing the protein samples in liquid
nitrogen.
Enzymatic Assay. The compounds were dissolved in DMSO. The
assays were performed at ﬁxed concentrations of ATP (0.5 mM) and
dTMP (0.05 mM) and at varying concentrations of tested compound
(between 0.0008 and 0.6 mM) using the spectrophotometric assay
described by Blondin et al.30 The reaction medium contains 50 mM
Tris-HCl, pH 7.4, 50 mM KCl, 2 mM MgCl2, 0.2 mM NADH, 1 mM
phosphoenol pyruvate, and 2 units each of coupling enzymes (lactate
dehydrogenase, pyruvate kinase and nucleoside diphosphate kinase).
IC50 values were calculated using KaleidaGraph. First the data points
were plotted and then best-ﬁt concentrations were generated using the
following equation: y = (m2)/(1 + (x/m3)
m4); where y = % inhibition;
m2 = ymax; m3 = IC50; m4 = slope of the curve at the midpoint; x = %
inhibition.
In Table S1 (Supporting Information), for each compound, column
2 indicates the IC50 values in μM, column 3 the number of data points
taken into account for the ﬁt, column 4 the number of compound
concentrations used to measure the residual TMPKmt activity, column
5 the maximum concentration tested, column 6 the minimum
concentration tested, and column 8 the coeﬃcient of determination
(R2).
Protein Crystallization. Cocrystallization conditions of
MtTMPK-inhibitor complexes were screened at 20 °C by the
sitting-drop vapor-diﬀusion method using a 1:1 protein/solution
volume ratio and available commercial screens. Before each
cocrystallization experiment, MtTMPK samples were thawed and
concentrated to 6−8 mg/mL. Compound 1 was initially dissolved in
Figure 6. Cocrystal structure of MtTMPK in complex with compound 43 and key interactions with the enzyme. (A). Compound 43 and the side
chains of interacting residues of MtTMPK are represented as sticks for carbon atoms and colored in white and orange, respectively. The
corresponding unbiased Fo-Fc electron density (contoured to +3 sigma) calculated before adding the ligand in the reﬁnement process is shown as a
green mesh. Protein is shown in a pale yellow cartoon representation. (B) Schematic drawing of the compound 43 binding site displaying key
MtTMPK residues in direct contact with 43. (Hydrogen bonds are represented with a red dashed line.)
Table 1. Inhibitory Activity of Compounds against MtTMPK
and M. tuberculosis cells (H37Ra and H37Rv Strains) and
Toxicity against MRC-5 Human Cell Line
compound
IC50
(μM)
MtMTPK MICa H37Rv
IC50
b
(μM)
H37Ra
IC50
b
(μM)
MRC-5
1 10 318.50 (125) >64 29.5
21 7.1 678.87 (>250) 60.45 47.85
24 142 650.29 (>250) >64 >64
35 9.0 678.87 (>250) >64 >64
42 1.1 35.25−70.62 (15.6−31.25) 32.51 8.35
43 0.95 16.35−32.70 (7.8−15.6) 0.96c 6.47
aMIC values are given in μM, and between brackets they are expressed
in μg/mL. bIC50 values were determined graphically using the plot of
the % viability as a function of compound concentration. cIC99 = 12.17
μM.
Table 2. Impact of Eﬄux on Antituberculosis Activity of MtTMPK Inhibitors
MIC (μg/mL)
M. tuberculosis strain H37Rv H37Rv H37Rv KO-Tap KO-Mmr
eﬄux inhibitor none verapamil PAβN none none
compound 1 125−31.25 15.6 62.5−31.25 31.25−62.5 31.25−15.63
compound 21 >250 31.25 >250 >31.25 15.63
compound 24 >250 >250 >250 >250 >250
compound 35 250 62.5−31.25 250 125 <1.95
compound 42 31.25−15.6 7.8 7.8 31.25−15.63 15.63
compound 43 7.8−15.6 3.9−7.8 7.8−15.6 7.8−15.6 7.8
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pure DMSO at a concentration of 100 mM and diluted to 50 mM
using pure isopropanol. Compound 43 was less soluble and initially
dissolved in pure DMSO at a concentration of 50 mM and diluted to
25 mM using pure isopropanol. Isopropanol appeared to be crucial in
improving solubility of compounds after dilution in protein buﬀer.
Diluted compounds were then added to a concentrated protein stock
at a ﬁnal concentration of 1 mM, and the protein/inhibitor sample was
incubated on ice for 1 h before setting up crystallization experiments.
For the MtTMPK/1 complex, the ligand stock solution at 50 mM in
50/50 (v/v) pure DMSO/pure isopropanol solution was added to the
concentrated protein solution stock to reach a ﬁnal inhibitor
concentration of 1 mM. To further increase the solubility of 1, a
50/50 (v/v) MtTMPK buﬀer/pure isopropanol solution was added to
the protein/inhibitor sample to increase the ﬁnal isopropanol
concentration from 1% (v/v) to 1.5% (v/v). An initial hit leading to
bipyramidal crystals was obtained in condition G6 (condition 30) of
the crystal screen II (0.1 M HEPES pH 7.5, 10% (w/v) PEG 6000 and
5% (v/v) MPD). The crystals were grown for a few weeks at room
temperature and exposed to a cryoprotection buﬀer obtained by the
combination of mother liquor supplemented with 1 mM compound 1
and 10% v/v PEG 400 before being mounted and ﬂash frozen in liquid
nitrogen.
Initial eﬀorts to obtain MtTMPK/43 cocrystals led to crystals with
very limited diﬀraction power. Better crystals were obtained using the
cross-seeding approach starting from in-house grown MtTMPK
crystals obtained with compound 43 related inhibitors. In short,
MtTMPK cocrystals initially grown in 0.1 M HEPES pH 6.8, 4.40 M
NaCl were crushed in 50 μL of a stabilizing solution (0.1 M HEPES
pH 6.8, 4.50 M NaCl, 1% (v/v) DMSO, 1% (v/v) isopropanol, 0.5
mM compound 43) using the seed bead kit (Hampton Research), and
serial dilutions of seeds with a stabilizing solution were performed. The
MtTMPK/43 sample was prepared as previously described for
compound 1 complex but using a lower protein concentration (6.0
mg/mL) and an initial ligand solution at 25 mM in 50/50 (v/v) pure
DMSO/pure isopropanol. Crystallization trials were setup at room
temperature using the contemporary seeding approach by mixing 0.3
μL of MtTMPK/compound 43 sample with 0.2 μL of a crystallization
solution and 0.1 μL of an undiluted or diluted seed stock. The best
diﬀracting crystal was obtained after a few weeks at room temperature
using the undiluted seed stock and crystallization solution consisting of
0.1 M HEPES pH 6.8, 4.35 M NaCl. This crystal was exposed to a
cryoprotection buﬀer (mother liquor supplemented with 1 mM
compound 43 and 10% v/v ethylene glycol) before being mounted
and ﬂash frozen in liquid nitrogen.
Data Collection, Structure Determination, and Reﬁnement.
Data collection of MtTMPK/1 cocrystal was achieved on Proxima1
beamline at Soleil synchrotron (Paris, France) at a wavelength of
0.978 57 Å and a temperature of 100 K on a Dectris Pilatus 6 M pixel
detector. Diﬀraction data from MtTMPK/43 cocrystal were collected
at beamline P14 operated by EMBL Hamburg at the PETRA III
storage ring (DESY, Hamburg, Germany) at a wavelength of 0.9763 Å
and a temperature of 100 K on a Dectris Pilatus 6 M pixel detector.
All data sets were indexed, processed, and scaled using XDS/
XSCALE, and mtz conversion was performed with XDSCONV.31 Five
percent of the randomly selected reﬂections were kept apart for cross-
validation and used for the calculation of Rfree. All structures were
solved by molecular replacement with PDB input ﬁles 4UNP for
MtTMPK/1 and 4UNR for MtTMPK/43 complex using MOLREP
from the CCP4 suite (Table S1).32 Structures were further reﬁned by
one cycle of rigid-body reﬁnement in BUSTER33 followed by
positional and individual isotropic B-factor reﬁnement in BUSTER
and PHENIX.34 Models were manually improved during the course of
the crystallographic reﬁnement using the program COOT.35 For the
MtTMPK/43, torsion NCS restraints where used throughout the
reﬁnement. Ligand coordinates were generated with the grade Web
Server (http://grade.globalphasing.org), which was also used for
energetic minimization and restraint generation. Ligand molecules
were modeled in sigma-weighted Fo-Fc diﬀerence electron density
maps in the course of the reﬁnement. TLS reﬁnement with one TLS
group deﬁnition per chain was applied in the latest stage of the
reﬁnement procedure after having all atoms B-factor reset to the
Wilson B-factor value. The real-space correlation coeﬃcient (RSCC) is
reported as an objective measure of the ﬁt of inhibitor coordinates to
electron density and was calculated using the Twilight program.36
Discovery studio visualizer version 16.1.0 (Dassault System̀es BIOVIA,
San Diego: Dassault System̀e) was used to analyze and describe the
binding mode of inhibitors within the protein. The quality of the ﬁnal
crystal structures was assessed with MOLPROBITY37 prior to
deposition at the PDB database under the codes 5NQ5 (MtTMPK/
1) and 5NR7 (MtTMPK/43). Molecular images were generated with
PyMOL (The PyMOL Molecular Graphics System, Schrödinger,
LLC). Data collection and reﬁnement statistics are presented in Table
S1 (Supporting Information).
Computational Studies. Ligand Eﬃciency (LE). According to eq
1, where HA stands for the number of non-hydrogen atoms of the
ligand and pKi for the negative logarithmic values of its corresponding
inhibition constant, ligand eﬃciency (average binding energy per
atom, Δg) values were calculated by using an Excel spreadsheet
(Supporting Information).38,39
= ×LE (1.37/HA) pIC50 (1)
Docking. All molecular modeling was calculated using the software
packages AutoDock 4.2 on Windows Cygwin and AutodockTools-
1.5.6. The X-ray structure of compound 1 in complex with MtTMPK
(PDB entry 5NQ5) was used in all docking experiments. The 2D
chemical structures and PDB ﬁles of the ligands were drawn and
created using ChemDraw 15 and ChembioDraw 15 separately. The
PDBQT ﬁle of the ligands and receptor were prepared by
AutodockTools-1.5.6, which include atomic partial charges, atom
types, and the information on the ligand torsional degrees. For the
docking, a default grid spacing of 0.375 Å and 60 × 60 × 60 number of
grid points were used, which centered the box on residue Phe70, at the
active site of MtTMPK (the coordinates x, y, z were −21.132, 31.018,
−12.924 correspondingly). Arg107 and Leu52 surrounding the
biphenyl ether tail (ring C and ring D) were set as ﬂexible residues.
The other settings such as search parameters and docking parameters
were adopted as default. A total of 50 possible conformations were
given by Autodock 4.2 for each docking. A manual selection
procedure, which combines visual inspection in AutodockTools-1.5.6
guided by Chimera together with the predicted free energy found for
each conformation, was used to validate the docked conformations.
In Vitro Antituberculosis Activity. Mycobacterium tuberculosis
strains used were the reference strain H37Rv,40,41 and the knockout
mutants, KO-Tap and KO-Mmr, were deleted, respectively, in genes
encoding the eﬄux pumps Tap42 and Mmr.43
Mycobacterium tuberculosis cultures were routinely grown at 37 °C in
Middlebrook 7H9 broth supplemented with 10% ADC (albumin,
dextrose, catalase supplement, Becton-Dickinson) and 0.05% Tween
80. The knockout mutant strains (KO-TAP and KO-Mmr) were
grown in the same medium supplemented with hygromycin at 50 μg/
mL. The minimum inhibitory concentration (MIC) was determined
using the Resazurin Microtiter Assay Plate.44 In 96-well plates, double
of the desired concentrations of the compounds were added in 100 μL
of Middlebrook 7H9 broth supplemented with 10% ADC and 0.5%
glycerol in a series of 2-fold dilutions, starting from 500 μg/mL. When
required, eﬄux pumps inhibitors were added to the medium, to a ﬁnal
concentration of 40 μg/mL for verapamil, and 15 μg/mL in the case of
PAßN. Bacteria were inoculated by adding 100 μL of a suspension of
105 cfu/mL, as determined by optical density, and prepared from a
culture in the exponential growth phase. Following inoculation, the
ﬁnal concentration of the compounds ranged from 250 μg/mL to 1.95
μg/mL. After 6 days of incubation at 37 °C, 30 μL of resazurin (0.01%
w/v) was added to each well, incubated for a further 48 h at 37 °C, and
assessed for color change. A change from blue to pink indicated
bacterial growth. The MIC is deﬁned as the lowest drug concentration
that prevents this color change. Changes in the MIC between strains
or experimental conditions were considered as signiﬁcant when there
was at least a 4-fold variation with the reference strain or condition.
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In vitro antimycobacterial activity of the 1,3-diaryltriazenides was
further evaluated by a luminometric assay based on a M. tuberculosis
H37Ra laboratory strain (ATCC 25177) transformed with a pSMT1
luciferase reporter plasmid (H37Ra-lux). A 2-fold serial dilution of
each compound was made in Middlebrook 7H9 broth and 10%
OADC (complete 7H9 broth) with ﬁnal concentrations ranging from
128 μM to 0.5 μM. Volumes of 100 μL of the serial dilutions were
added in triplicate to black, ﬂat-bottomed 96-well plates. As a positive
control, isoniazid, a ﬁrst-line antimycobacterial drug, was included.
The mycobacterial suspension was made by thawing a frozen glycerol-
stock of H37Ra-lux and, subsequently, diluting it in complete 7H9
broth to obtain a suspension with 10.000 relative light units (RLU)/
mL. A volume of 100 μL of bacteria was added to each well. All of the
outer-perimeter wells were ﬁlled with 200 μL of sterile deionized water
to minimize evaporation of the medium in the test wells during
incubation. After 7 days, the bacterial replication was analyzed by
luminometry. To evoke a luminescent signal, 25 μL of 1% n-decanal in
ethanol was added to each well, where after light emission was
measured using a luminometer (Promega Discover).
In Vitro Cytotoxicity Assay. In vitro cytotoxicity on the MRC-5
Homo sapiens long ﬁbroblast cell line (ATCC CCL-171) was assessed
for each analogue by a NRU assay. The MRC-5 cells were cultured in a
75 cm2 sterile Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal calf serum in a 5%
CO2 atmosphere at 37 °C. When a semiconﬂuent layer of cells was
formed, the cells were trypsinized, washed with sterile PBS, seeded
into a transparent, ﬂat-bottomed 96-well plate at a density of 4 × 104
cells per well, and left for recovery at 37 °C, 5% CO2. For each
compound, a 2-fold serial dilution was made in complete DMEM with
ﬁnal concentrations ranging from 128 μM to 0.5 μM. Subsequently,
the MRC-5 cells were exposed to the compounds (in triplicate) by
adding 100 μL of the serial dilutions to the wells. Test plates were
incubated for 24 h in an atmosphere of 5% CO2 at 37 °C. For the
NRU assay, the cells were washed 2 times with 200 μL of PBS and 100
μL of the neutral red working solution was added per well.
Subsequently, the plates were left for incubation at 37 °C, 5% CO2
for 3 h. After incubation, the wells were washed 2 times with 200 μL of
PBS and 150 μL of an ethanol/acetic acid mixture was added per well.
The plates were left shaking until the color became homogeneous
purple, and the optical density was measured at 530 and 620 nm
(reference wavelength) using a Promega Discover plate reader.
■ CHEMISTRY
General. Solvents were purchased from standard commer-
cial sources and were of analytical grade. Building blocks and
reagents were used as received without any further puriﬁcation.
TLC analysis was performed using precoated Alugram Silica
Gel F254 plates (Machery-Nagel). Spots were examined under
ultraviolet light at 254 nm. Column chromatography was
carried out on a Reveleris X2 (Grace) automated ﬂash unit
using the corresponding disposable silica gel cartridges. 1H and
13C NMR spectra were recorded in CDCl3 or DMSO-d6 on a
Varian Mercury 300/75 MHz spectrometer. Chemical shifts are
given in parts per million (ppm δ), δ relative to the residual
solvent peak or TMS for 1H and 13C. Structural assignment was
conﬁrmed with COSY, HSQC, and HMBC. Exact mass
measurements (HRMS) were performed on a Waters LCT
Premier XETM time of ﬂight (TOF) mass spectrometer
equipped with a standard electrospray ionization (ESI) and
modular LockSpray TM interface. Samples were infused in a
CH3CN/H2O (1:1) mixture at 100 μL/min. Preparative
reversed phase HPLC chromatography was carried out using
a Phenomenex Luna C-18 (21.2 mm × 250 mm) column using
a linear gradient from 10% MeCN to 100% MeCN in a 10 mM
ammonium bicarbonate solution over 20 min and a ﬂow rate of
17.5 mL/min. The purity of all ﬁnal compounds was
determined by LC-MS analyses on a Waters Alliance 2695
XE separation module using a Phenomenex Kinetex EVO C18,
5um 100 mm × 2.1 mm column and a gradient system of
HCOOH in H2O (0.1%, v/v)/HCOOH in CH3CN (0.1%, v/
v) at a ﬂow rate of 0.6 mL/min, 05:95 to 0:100 (5 to 100%
CH3CN) in 8 min. All ﬁnal compounds showed >95% purity.
General Procedure for the Synthesis of Final
Compounds. A suspension of azaheterocyclic or aminoalkyl
thymine (1 equiv), substituted aromatic aldehyde (1−2 equiv),
and sodium triacetoxyborohydride (1.5−4 equiv) in dry 1,2-
dichloroethane (∼0.03 M) was stirred at room temperature
under argon overnight or 48 h. The reaction mixture was
evaporated and dried with an oil pump for 0.5 h. The residue
was puriﬁed by column chromatography (10% ethyl acetate/
hexane and 0.8% Et3N−100% ethyl acetate and 0.8% Et3N or
100% CH2Cl2−10% MeOH/CH2Cl2 or 100% ethyl acetate−
5% MeOH/ethyl acetate in a linear gradient elution) to aﬀord
the pure intermediate, followed by BOM-deprotection. There
are two methods for the BOM-deprotection step. For method
1, according to a literature procedure,45 the intermediate was
dissolved with TFA (∼0.05 M) under argon. The reaction
mixture was stirred at 72 °C for 30 min to 1 h. The reaction
progress was monitored by HRMS. Once the starting material
was consumed completely, the reaction mixture was cooled to
room temperature, concentrated in a vacuum, and dried with an
oil pump. The residue was dissolved with the solvent mixture
(1−2 mL, MeCN/t-BuOH/H2O, v/v/v = 1/1/1 or acetic acid
or H2O) and puriﬁed with preparative HPLC. After
lyophilization, all of the products were obtained as white
powders. For method 2, the intermediate was dissolved with
80% TFA/H2O (∼0.01 M), and L-cysteine hydrochloride (0.25
or 0.27 M) was added to the reaction mixture. The reaction
mixture was stirred at 72 °C for 5−16 h. HRMS was used to
monitor the reaction progress. Once the starting material was
consumed completely, the reaction mixture was cooled to room
temperature and evaporated. The residue was puriﬁed with
preparative HPLC.
5-Methyl-1-(1-(3-phenoxybenzyl)piper idin-4-yl ) -
pyrimidine-2,4(1H,3H)-dione (2). Following the General
Procedure for the Synthesis of Final Compounds (method
1), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (86.3 mg, 0.262 mmol), 3-
phenoxybenzaldehyde (77.9 mg, 0.393 mmol), and sodium
triacetoxyborohydride (111.1 mg, 0.524 mmol) in dry 1,2-
dichloroethane (10 mL) using the ethyl acetate−hexane eluent
system to obtain the intermediate, which was dissolved with
TFA (8 mL), yielded compound 2 (39.6 mg, 39%). 1H NMR
(300 MHz, DMSO-d6): δ 1.64 (d, J = 9.38 Hz, 2H, piperidin-
3a-yl, piperidin-5a-yl), 1.73−1.93 (m, 5H, piperidin-3b-yl,
piperidin-5b-yl, 5-CH3), 1.98−2.12 (m, 2H, piperidin-2a-yl,
piperidin-6a-yl), 2.90 (d, J = 11.43 Hz, 2H, piperidin-2b-yl,
piperidin-6b-yl), 3.49 (s, 2H, CH2, 1-methylene), 4.25 (ddd, J =
12.02, 8.06, 4.25 Hz, 1H, piperidin-4-yl), 6.87 (dd, J = 8.06,
2.49 Hz, 1H, Ph), 6.97−7.03 (m, 3H, Ph), 7.06−7.16 (m, 2H,
Ph), 7.30−7.43 (m, 3H, Ph), 7.63 (s, 1H, H-6), 11.18 (s, 1H,
NH). 13C NMR (75 MHz, DMSO-d6): δ 12.00 (5-CH3), 29.98
(2C, piperidin-3-yl, piperidin-5-yl), 52.33 (3C, piperidin-2-yl,
piperidin-6-yl, piperidin-4-yl), 61.23 (1-methylene), 108.93 (C-
5), 117.17 (Ph), 118.47 (2C, Ph), 118.78 (Ph), 123.35 (Ph),
123.86 (Ph), 129.75 (Ph), 130.06 (2C, Ph), 137.69 (C-6),
140.92 (Ph), 150.82 (C-2), 156.57 (Ph), 156.75 (Ph), 163.68
(C-4). HRMS (ESI): calcd for [C23H25N3O3 + H]
+, 392.1969;
found, 392.1974.
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5-Methyl-1-(1-(3-phenoxyphenethyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (3). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (93.9 mg, 0.285 mmol), 2-
(3-phenoxyphenyl)acetaldehyde 50 (120.0 mg, 0.57 mmol),
and sodium triacetoxyborohydride (151.0 mg, 0.713 mmol) in
dry 1,2-dichloroethane (10 mL) using the ethyl acetate−hexane
eluent system to obtain the intermediate, which was dissolved
with 80% TFA/H2O (32 mL), and the addition of L-cysteine
hydrochloride (1.40 g, 8.88 mmol) to the reaction mixture
yielded compound 3 (59.0 mg, 51%). 1H NMR (300 MHz,
DMSO-d6): δ 1.59−1.69 (m, 2H), 1.72−1.91 (m, 5H), 2.05 (t,
J = 10.69 Hz, 2H), 2.53−2.61 (m, 2H), 2.67−2.79 (m, 2H),
3.02 (d, J = 11.72 Hz, 2H), 4.16−4.32 (m, 1H), 6.82 (dt, J =
8.13, 1.21 Hz, 1H), 6.89−6.94 (m, 1H), 6.96−7.05 (m, 3H),
7.09−7.16 (m, 1H), 7.29 (t, J = 7.91 Hz, 1H), 7.34−7.43 (m,
2H), 7.61 (d, J = 1.17 Hz, 1H), 11.20 (s, 1H). 13C NMR (75
MHz, DMSO-d6): δ 12.01, 29.99 (2C), 32.77, 52.39 (2C),
52.48, 59.00, 108.88, 116.12, 118.47 (2C), 118.99, 123.26,
123.86, 129.75, 129.99 (2C), 137.64, 142.83, 150.80, 156.49,
156.75, 163.67. HRMS (ESI): calcd for [C24H27N3O3 + H]
+,
406.2125; found, 406.2175.
5-Methyl-1-(1-(4-phenoxybenzyl)piper idin-4-yl ) -
pyrimidine-2,4(1H,3H)-dione (4). Following the General
Procedure for the Synthesis of Final Compounds (method
1), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (80.0 mg, 0.243 mmol), 4-
phenoxybenzaldehyde (72.3 mg, 0.365 mmol), and sodium
triacetoxyborohydride (103.0 mg, 0.486 mmol) in dry 1,2-
dichloroethane (10 mL) using the ethyl acetate−hexane eluent
system to obtain the intermediate, which was dissolved with
TFA (10 mL), yielded compound 4 (34.5 mg, 36%) and the
corresponding dimer 73 (20.3 mg). Compound 4. 1H NMR
(300 MHz, DMSO-d6): δ 1.64 (d, J = 9.37 Hz, 2H, piperidin-
3a-yl, piperidin-5a-yl), 1.72−1.92 (m, 5H, piperidin-3b-yl,
piperidin-5b-yl, 5-CH3), 2.04 (t, J = 10.84 Hz, 2H, piperidin-
2a-yl, piperidin-6a-yl), 2.91 (d, J = 11.72 Hz, 2H, piperidin-2b-
yl, piperidin-6b-yl), 3.46 (s, 2H, CH2, 1-methylene), 4.19−4.33
(m, 1H, piperidin-4-yl), 6.93−7.01 (m, 4H, Ph), 7.08−7.15 (m,
1H, Ph), 7.26−7.41 (m, 4H, Ph), 7.63 (d, J = 1.17 Hz, 1H, H-
6), 11.18 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6): δ
11.99 (5-CH3), 29.96 (2C, piperidin-3-yl, piperidin-5-yl), 52.26
(2C, piperidin-2-yl, piperidin-6-yl), 52.35 (piperidin-4-yl),
61.01 (CH2, 1-methylene), 108.92 (C-5), 118.37 (2C, Ph),
118.46 (2C, Ph), 123.33 (Ph), 130.02 (4C, Ph), 130.43 (Ph),
137.70 (C-6), 150.81 (C-2), 155.54 (Ph), 156.78 (Ph), 163.66
(C-4). HRMS (ESI): calcd for [C23H25N3O3 + H]
+, 392.1969;
found, 392.1972. Dimer 73. 1H NMR (300 MHz, DMSO-d6): δ
1.65 (m, 4H, piperidin-3a-yl, piperidin-5a-yl), 1.75−1.88 (m,
10H, piperidin-3b-yl, piperidin-5b-yl, 5-CH3), 2.05 (t, J = 10.70
Hz, 4H, piperidin-2a-yl, piperidin-6a-yl), 2.91 (d, J = 11.73 Hz,
4H, piperidin-2b-yl, piperidin-6b-yl), 3.46 (s, 4H, CH2, 1-
methylene), 3.91 (s, 2H, methylene), 4.19−4.33 (m, 2H,
piperidin-4-yl), 6.90−6.97 (m, 8H, Ph), 7.22−7.31 (m, 8H,
Ph), 7.63 (d, J = 0.88 Hz, 2H, H-6), 11.18 (s, 2H, NH). 13C
NMR (75 MHz, DMSO-d6): δ 12.00 (2C, 5-CH3), 29.95 (4C,
piperidin-3-yl, piperidin-5-yl), 40.00 (1C, methylene), 52.25
(4C, piperidin-2-yl, piperidin-6-yl), 52.36 (2C, piperidin-4-yl),
61.00 (2C, CH2, 1-methylene), 108.91 (2C, C-5), 118.10 (4C,
Ph), 118.68 (4C, Ph), 130.13 (4C, Ph), 130.39 (4C, Ph),
136.42 (2C, Ph), 137.69 (2C, C-6), 150.80 (2C, C-2), 154.91
(2C, Ph), 155.82 (2C, Ph), 163.65 (2C, C-4). HRMS (ESI):
calcd for [C47H50N6O6 + H]
+, 795.3865; found, 795.3862.
5-Methyl-1-((1-(3-phenoxybenzyl)piperidin-4-yl)methyl)-
pyrimidine-2,4(1H,3H)-dione (5). Following the General
Procedure for the Synthesis of Final Compounds (method
1), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-ylmethyl)-
pyrimidine-2,4(1H,3H)-dione 65 (144.2 mg, 0.42 mmol), 3-
phenoxybenzaldehyde (166.5 mg, 0.84 mmol), and sodium
triacetoxyborohydride (267.1 mg, 1.26 mmol) in dry 1,2-
dichloroethane (15 mL) using the ethyl acetate−hexane eluent
system to obtain the intermediate, which was dissolved with
TFA (10 mL), yielded compound 5 (68.1 mg, 40%). 1H NMR
(300 MHz, DMSO-d6): δ 1.08−1.26 (m, 2H, piperidin-3a-yl,
piperidin-5a-yl), 1.50 (d, J = 12.01 Hz, 2H, piperidin-3b-yl,
piperidin-5b-yl), 1.57−1.71 (m, 1H, piperidin-4-yl), 1.74 (s,
3H, 5-CH3), 1.88 (t, J = 11.13 Hz, 2H, piperidin-2a-yl,
piperidin-6a-yl), 2.78 (d, J = 11.13 Hz, 2H, piperidin-2b-yl,
piperidin-6b-yl), 3.44 (s, 2H, CH2, 1-methylene), 3.50 (d, J =
7.03 Hz, 2H, CH2, N-methylene), 6.82−7.09 (m, 5H, Ph),
7.09−7.18 (m, 1H, Ph), 7.27−7.44 (m, 3H, Ph), 7.48 (s, 1H,
H-6), 11.20 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6): δ
11.94 (5-CH3), 29.03 (2C, piperidin-3-yl, piperidin-5-yl), 34.91
(piperidin-4-yl), 52.36 (CH2, N-methylene), 52.56 (2C,
piperidin-2-yl, piperidin-6-yl), 61.68 (CH2, 1-methylene),
108.11 (C-5), 117.02 (Ph), 118.47 (Ph), 118.56 (2C, Ph),
123.37 (Ph), 123.64 (Ph), 129.70 (Ph), 130.03 (2C, Ph),
141.00 (Ph), 141.87 (C-6), 151.03 (C-2), 156.63 (Ph), 156.68
(Ph), 164.25 (C-4). HRMS (ESI): calcd for [C24H27N3O3 +
H]+, 406.2125; found, 406.2130.
5-Methyl-1-((1-(4-phenoxybenzyl)piperidin-4-yl)methyl)-
pyrimidine-2,4(1H,3H)-dione (6). Following the General
Procedure for the Synthesis of Final Compounds (method
1), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-ylmethyl)-
pyrimidine-2,4(1H,3H)-dione 65 (171.7 mg, 0.50 mmol), 4-
phenoxybenzaldehyde (198.2 mg, 1.0 mmol), and sodium
triacetoxyborohydride (317.9 mg, 1.5 mmol) in dry 1,2-
dichloroethane (15 mL) using the ethyl acetate−hexane eluent
system to obtain the intermediate, which was dissolved with
TFA (10 mL), yielded compound 6 (38.0 mg, 19%). 1H NMR
(300 MHz, DMSO-d6): δ 1.12−1.31 (m, 2H, piperidin-3a-yl,
piperidin-5a-yl), 1.54 (d, J = 11.13 Hz, 2H, piperidin-3b-yl,
piperidin-5b-yl), 1.61−1.80 (m, 4H, piperidin-4-yl, 5-CH3),
1.86−2.09 (m, 2H, piperidin-2a-yl, piperidin-6a-yl), 2.85 (d, J =
10.54 Hz, 2H, piperidin-2b-yl, piperidin-6b-yl), 3.51 (d, J = 6.74
Hz, 4H, 2CH2, 1-methylene, N-methylene), 6.97 (t, J = 9.08
Hz, 4H, Ph), 7.13 (t, J = 7.32 Hz, 1H, Ph), 7.19−7.44 (m, 4H,
Ph), 7.48 (H-6), 11.21 (s, 1H, NH). 13C NMR (75 MHz,
DMSO-d6): δ 11.94 (5-CH3), 28.74 (2C, piperidin-3-yl,
piperidin-5-yl), 34.77 (piperidin-4-yl), 52.25 (CH2, N-methyl-
ene), 52.34 (2C, piperidin-2-yl, piperidin-6-yl), 61.18 (CH2, 1-
methylene), 108.15 (C-5), 118.39 (2C, Ph), 118.50 (2C, Ph),
123.35 (Ph), 130.03 (Ph), 130.54 (Ph), 141.84 (C-6), 151.06
(C-2), 155.66 (Ph), 156.75 (Ph), 164.25 (C-4). HRMS (ESI):
calcd for [C24H27N3O3 + H]
+, 406.2125; found, 406.2142.
5-Methyl-1-(1-(3-phenoxybenzyl)azetidin-3-yl)pyrimidine-
2,4(1H,3H)-dione (7). Following the General Procedure for the
Synthesis of Final Compounds (method 2), 3-((benzyloxy)-
methyl)-1-(azetidin-3-yl)-3-((benzyloxy)methyl)-5-methylpyri-
midine-2,4(1H,3H)-dione 67 (90.4 mg, 0.3 mmol), 3-
phenoxybenzaldehyde (118.9 mg, 0.6 mmol), and sodium
triacetoxyborohydride (127.2 mg, 0.6 mmol) in dry 1,2-
dichloroethane (10 mL) using the ethyl acetate−hexane eluent
system to obtain the intermediate, which was dissolved with
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80% TFA/H2O (30 mL), and the addition of L-cysteine
hydrochloride (1.28 g, 8.1 mmol) to the reaction mixture
yielded compound 7 (46.9 mg, 43%). 1H NMR (300 MHz,
DMSO-d6): δ 1.77 (d, J = 0.59 Hz, 3H), 3.19 (t, J = 7.18 Hz,
2H), 3.53 (t, J = 7.76 Hz, 2H), 3.62 (s, 2H), 4.75 (quin, J =
6.66 Hz, 1H), 6.83−6.93 (m, 2H), 6.95−7.07 (m, 3H), 7.08−
7.17 (m, 1H), 7.27−7.43 (m, 3H), 7.66 (d, J = 0.88 Hz, 1H),
11.23 (s, 1H). 13C NMR (75 MHz, DMSO-d6): δ 12.12, 46.05,
58.89 (2C), 61.49, 108.99, 117.07, 117.94, 118.73 (2C), 123.20,
123.48, 129.86, 130.04 (2C), 137.78, 140.42, 150.69, 156.54,
156.78, 163.85. HRMS (ESI): calcd for [C21H21N3O3 + H]
+,
364.1656; found, 364.1675.
5-Methyl-1-(1-(3-phenoxyphenethyl)azetidin-3-yl)-
pyrimidine-2,4(1H,3H)-dione (8). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-1-(azetidin-3-yl)-3-((benzyloxy)-
methyl)-5-methylpyrimidine-2,4(1H,3H)-dione 67 (114.5 mg,
0.38 mmol), 2-(3-phenoxyphenyl)acetaldehyde 50 (120.0 mg,
0.57 mmol), and sodium triacetoxyborohydride (161.1 mg, 0.76
mmol) in dry 1,2-dichloroethane (10 mL) using the ethyl
acetate−methanol eluent system to obtain the intermediate,
which was dissolved with 80% TFA/H2O (30 mL), and the
addition of L-cysteine hydrochloride (1.32 g, 8.37 mmol) to the
reaction mixture yielded compound 8 (38.0 mg, 26%). 1H
NMR (300 MHz, DMSO-d6): δ 1.79 (d, J = 0.88 Hz, 3H),
2.54−2.62 (m, 2H), 2.63−2.71 (m, 2H), 3.11−3.20 (m, 2H),
3.49−3.59 (m, 2H), 4.74 (quin, J = 6.52 Hz, 1H), 6.81 (ddd, J
= 8.05, 2.49, 0.88 Hz, 1H), 6.89−6.93 (m, 1H), 6.95−7.04 (m,
3H), 7.12 (tt, J = 7.36, 1.13 Hz, 1H), 7.29 (t, J = 7.76 Hz, 1H),
7.33−7.43 (m, 2H), 7.69 (d, J = 1.17 Hz, 1H), 11.25 (br s, 1H).
13C NMR (75 MHz, DMSO-d6): δ 12.10, 33.38, 46.04, 59.03
(2C), 59.50, 108.98, 116.15, 118.42 (2C), 119.05, 123.26,
123.90, 129.67, 129.98 (2C), 137.78, 142.45, 150.69, 156.43,
156.75, 163.85. HRMS (ESI): calcd for [C22H23N3O3 + H]
+,
378.1812; found, 378.1829.
5-Methyl-1-(1-(3-(3-phenoxyphenyl)propyl)azetidin-3-yl)-
pyrimidine-2,4(1H,3H)-dione (9). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-1-(azetidin-3-yl)-3-((benzyloxy)-
methyl)-5-methylpyrimidine-2,4(1H,3H)-dione 67 (98.4 mg,
0.327 mmol), 3-(3-phenoxyphenyl)propanal 52 (147.7 mg,
0.653 mmol), and sodium triacetoxyborohydride (138.4 mg,
0.653 mmol) in dry 1,2-dichloroethane (10 mL) using the ethyl
acetate−methanol eluent system to obtain the intermediate,
which was dissolved with 80% TFA/H2O (30 mL), and the
addition of L-cysteine hydrochloride (1.32 g, 8.37 mmol) to the
reaction mixture yielded compound 9 (40.0 mg, 31%). 1H
NMR (300 MHz, DMSO-d6): δ 1.57 (quin, J = 7.25 Hz, 2H),
1.80 (s, 3H), 2.43 (br s, 2H), 2.58 (t, J = 7.62 Hz, 2H), 3.12 (br
s, 2H), 3.53 (t, J = 6.59 Hz, 2H), 4.74 (quin, J = 6.44 Hz, 1H),
6.80 (dd, J = 7.91, 2.05 Hz, 1H), 6.85 (t, J = 1.76 Hz, 1H),
6.95−7.03 (m, 3H), 7.09−7.17 (m, 1H), 7.29 (t, J = 7.91 Hz,
1H), 7.34−7.43 (m, 2H), 7.69 (d, J = 1.17 Hz, 1H), 11.26 (s,
1H). 13C NMR (75 MHz, DMSO-d6): δ 12.10, 28.76, 32.56,
46.07, 57.61, 58.98 (2C), 108.96, 115.95, 118.50 (2C), 118.55,
123.29, 123.48, 129.80, 129.98 (2C), 137.81, 144.33, 150.71,
156.57, 156.72, 163.87. HRMS (ESI): calcd for [C23H25N3O3 +
H]+, 392.1969; found, 392.1962.
5-Methyl-1-(1-(4-phenoxybenzyl)azetidin-3-yl)pyrimidine-
2,4(1H,3H)-dione (10). Following the General Procedure for
the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-1-(azetidin-3-yl)-3-((benzyloxy)methyl)-
5-methylpyrimidine-2,4(1H,3H)-dione 67 (81.4 mg, 0.27
mmol), 4-phenoxybenzaldehyde (107.1 mg, 0.54 mmol), and
sodium triacetoxyborohydride (114.5 mg, 0.54 mmol) in dry
1,2-dichloroethane (8 mL) using the ethyl acetate−hexane
eluent system to obtain the intermediate, which was dissolved
with 80% TFA/H2O (30 mL), and the addition of L-cysteine
hydrochloride (1.28 g, 8.1 mmol) to the reaction mixture
yielded compound 10 (39.4 mg, 40%). 1H NMR (300 MHz,
DMSO-d6): δ 1.81 (d, J = 1.17 Hz, 3H), 3.22 (t, J = 7.32 Hz,
2H), 3.53−3.61 (m, 2H), 3.63 (s, 2H), 4.77 (quin, J = 6.74 Hz,
1H), 6.92−7.03 (m, 4H), 7.09−7.17 (m, 1H), 7.27−7.34 (m,
2H), 7.34−7.43 (m, 2H), 7.71 (d, J = 1.17 Hz, 1H), 11.26 (s,
1H). 13C NMR (75 MHz, DMSO-d6): δ 12.10, 46.11, 58.85
(2C), 61.30, 108.98, 118.44 (2C), 118.52 (2C), 123.35, 129.87
(2C), 130.01 (2C), 133.14, 137.84, 150.71, 155.58, 156.74,
163.88. HRMS (ESI): calcd for [C21H21N3O3 + H]
+, 364.1656;
found, 364.1661.
5-Methyl-1-(3-(methyl(3-phenoxybenzyl)amino)propyl)-
pyrimidine-2,4(1H,3H)-dione (11). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(2-(methylamino)-
ethyl)pyrimidine-2,4(1H,3H)-dione 69 (95.2 mg, 0.3 mmol),
3-phenoxybenzaldehyde (118.9 mg, 0.6 mmol), and sodium
triacetoxyborohydride (127.2 mg, 0.6 mmol) in dry 1,2-
dichloroethane (8 mL) using the ethyl acetate−hexane eluent
system to obtain the intermediate, which was dissolved with
80% TFA/H2O (32 mL), and the addition of L-cysteine
hydrochloride (1.40 g, 8.88 mmol) to the reaction mixture
yielded compound 11 (71.3 mg, 65%). 1H NMR (300 MHz,
DMSO-d6): δ 1.66−1.80 (m, 5H), 2.10 (s, 3H), 2.32 (t, J =
6.00 Hz, 2H), 3.44 (br s, 2H), 3.61 (t, J = 7.03 Hz, 2H), 6.85−
7.03 (m, 4H), 7.04−7.17 (m, 2H), 7.29−7.42 (m, 3H), 7.43−
7.48 (m, 1H), 11.18 (s, 1H). 13C NMR (75 MHz, DMSO-d6):
δ 11.94, 26.01, 41.53, 45.66, 53.47, 61.01, 108.24, 117.08,
118.56, 118.64 (2C), 123.40, 123.74, 129.72, 130.03 (2C),
141.43, 141.57, 150.82, 156.68 (2C), 164.30. HRMS (ESI):
calcd for [C22H25N3O3 + H]
+, 380.1969; found, 380.1962.
5-Methyl-1-(2-(methyl(3-phenoxybenzyl)amino)ethyl)-
pyrimidine-2,4(1H,3H)-dione (12). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(3-(methylamino)-
propyl)pyrimidine-2,4(1H,3H)-dione 71 (91.0 mg, 0.3
mmol), 3-phenoxybenzaldehyde (118.9 mg, 0.6 mmol), and
sodium triacetoxyborohydride (127.2 mg, 0.6 mmol) in dry 1,2-
dichloroethane (8 mL) using the ethyl acetate−hexane eluent
system to obtain the intermediate, which was dissolved with
80% TFA/H2O (32 mL), and the addition of L-cysteine
hydrochloride (1.40 g, 8.88 mmol) to the reaction mixture
yielded compound 12 (61.1 mg, 56%). 1H NMR (300 MHz,
DMSO-d6): δ 1.72 (3H), 2.24 (br s, 3H), 2.57 (br s, 2H), 3.55
(br s, 2H), 3.75 (br s, 2H), 6.79−7.05 (m, 5H), 7.12 (t, J = 7.32
Hz, 1H), 7.28 (t, J = 7.76 Hz, 1H), 7.32−7.47 (m, 3H), 11.17
(br s, 1H). 13C NMR (75 MHz, DMSO-d6): δ 11.91, 41.87,
44.51, 54.72, 60.77, 107.75, 117.29, 118.44 (2C), 118.90,
123.29, 123.74, 129.67, 129.99 (2C), 141.93 (2C), 150.91,
156.54, 156.75, 164.28. HRMS (ESI): calcd for [C21H23N3O3 +
H]+, 366.1812; found, 366.1801.
5-Methyl-1-(1-(3-phenoxybenzoyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (13). According to a literature
procedure,24 to the reaction mixture of 3-((benzyloxy)methyl)-
5-methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione 63
(148.2 mg, 0.45 mmol) and 3-phenoxybenzoic acid (144.6
mg, 0.675 mmol) in dichloromethane (10 mL) were added 1-
ethyl-3-(3-(dimethylamino)propyl)carbodiimide (139.7 mg,
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0.90 mmol) and 4-dimethylaminopyridine (1.5 mg) at room
temperature under argon. The reaction mixture was stirred
overnight and diluted with CH2Cl2 (50 mL). The mixture was
washed with water (50 mL) and brine (50 mL) sequentially.
The organic layer was dried over Na2SO4 and concentrated in a
vacuum. The residue was puriﬁed by column chromatography
(25% ethyl acetate/hexane−65% ethyl acetate/hexane in a
linear gradient elution) to give the amide intermediate, which
was subsequently dissolved in EtOH (10 mL), and Pd/C (0.15
g) was added. The reaction was stirred under hydrogen for 6 h;
the suspension was ﬁltered, and the ﬁltrate evaporated and was
dried with an oil pump vacuum for 0.5 h. The residue was
dissolved in a mixture of THF/H2O (10 mL, v/v = 2/1) and
stirred for 4 h. After evaporation, the residue was puriﬁed with
column chromatography (1% MeOH/CH2Cl2−10% MeOH/
CH2Cl2 in a linear gradient elution). After lyophilization, the
desired product 13 was obtained as a white powder (45.0 mg,
25%). 1H NMR (300 MHz, DMSO-d6, 80 °C): δ 1.63−1.87
(m, 7H, piperidin-3-yl, piperidin-5-yl, 5-CH3), 2.89−3.02 (m,
2H, piperidin-2a-yl, piperidin-6a-yl), 4.00−4.29 (m, 2H,
piperidin-2b-yl, piperidin-6b-yl), 4.47−4.64 (m, 1H, piperidin-
4-yl), 7.01−7.12 (m, 4H, Ph), 7.13−7.21 (m, 2H, Ph), 7.37−
7.50 (m, 3H, Ph), 7.56 (d, J = 1.17 Hz, 1H, H-6), 10.91 (br s,
1H, NH). 13C NMR (75 MHz, DMSO-d6, 60 °C): δ 11.60 (5-
CH3), 29.72 (2C, piperidin-3-yl, piperidin-5-yl), 51.81 (piper-
idin-4-yl), 108.76 (C-5), 116.29 (Ph), 118.78 (2C, Ph), 119.00
(Ph), 121.19 (Ph), 123.61 (Ph), 129.86 (2C, Ph), 129.93 (Ph),
137.29 (C-6), 137.81 (Ph), 150.48 (C-2), 155.99 (Ph), 156.66
(Ph), 163.32 (C-4), 167.85 (CO). C (piperidin-2-yl) and C
(piperidin-6-yl) could not be found. HRMS (ESI): calcd for
[C23H23N3O4 + H]
+, 406.1761; found, 406.1752.
5-Methyl-1-(1-(4-phenoxybenzoyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (14). According to a literature
procedure,24 to 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-
4-yl)pyrimidine-2,4(1H,3H)-dione 63 (148.2 mg, 0.45 mmol)
and 4-phenoxybenzoic acid (144.6 mg, 0.68 mmol) in dry
dichloromethane (CH2Cl2, 10 mL) were added EDC (139.7
mg, 0.90 mmol) and 4-DMAP (1.5 mg) at room temperature
under argon. The desired compound 14 was obtained as a
white powder (170.0 mg, 93%). 1H NMR (300 MHz, DMSO-
d6, 50 °C): δ 1.74−1.92 (m, 7H), 3.02 (t, J = 11.57 Hz, 2H),
4.19 (br s, 2H), 4.51−4.66 (m, 1H), 7.01−7.11 (m, 4H), 7.15−
7.23 (m, 1H), 7.38−7.51 (m, 4H), 7.64 (s, 1H). 13C NMR (75
MHz, CDCl3): δ 12.61, 30.33 (2C), 30.97 (br s) 44.06 (2C),
52.65, 77.23, 111.39, 118.00 (2C), 119.71 (2C), 124.21, 129.20
(2C), 129.49, 129.98 (2C), 135.69, 150.71, 156.04, 159.29,
163.15, 170.28. HRMS (ESI): calcd for [C23H23N3O4 + H]
+,
406.1761; found, 406.1764.
1-(1-Benzylpiperidin-4-yl)-5-methylpyrimidine-2,4(1H,3H)-
dione (15). Following the General Procedure for the Synthesis
of Final Compounds (method 2), 3-((benzyloxy)methyl)-5-
methyl-1-(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione 63
(131.8 mg, 0.4 mmol), benzaldehyde (84.9 mg, 0.8 mmol),
and sodium triacetoxyborohydride (169.6 mg, 0.8 mmol) in dry
1,2-dichloroethane (10 mL) using the ethyl acetate−hexane
eluent system to obtain the intermediate, which was dissolved
with 80% TFA/H2O (28 mL), and the addition of L-cysteine
hydrochloride (1.19 g, 7.59 mmol) to the reaction mixture
yielded compound 15 (75.1 mg, 68%). 1H NMR (300 MHz,
DMSO-d6): δ 1.64 (d, J = 9.37 Hz, 2H), 1.73−1.94 (m, 5H),
1.97−2.13 (m, 2H), 2.90 (d, J = 11.42 Hz, 2H), 3.49 (s, 2H),
4.26 (tt, J = 12.08, 3.88 Hz, 1H), 7.21−7.37 (m, 5H), 7.65 (d, J
= 1.17 Hz, 1H), 11.19 (s, 1H). 13C NMR (75 MHz, DMSO-
d6): δ 12.00, 30.01 (2C), 52.36, 52.40 (2C), 61.75, 108.94,
126.94, 128.15 (2C), 128.80 (2C), 137.70, 138.47, 150.82,
163.68. HRMS (ESI): calcd for [C17H21N3O2 + H]
+, 300.1707;
found, 300.1705.
5-Methyl-1-(1-(3-methylbenzyl)piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione (16). Following the General Procedure for
the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol), 3-methylbenzal-
dehyde (96.1 mg, 0.8 mmol), and sodium triacetoxyborohy-
dride (169.6 mg, 0.8 mmol) in dry 1,2-dichloroethane (10 mL)
using the ethyl acetate−hexane eluent system to obtain the
intermediate, which was dissolved with 80% TFA/H2O (30
mL), and the addition of L-cysteine hydrochloride (1.28 g, 8.10
mmol) to the reaction mixture yielded compound 16 (75.2 mg,
60%). 1H NMR (300 MHz, DMSO-d6): δ 1.64 (d, J = 9.37 Hz,
2H), 1.74−1.92 (m, 5H), 1.96−2.10 (m, 2H), 2.30 (s, 3H),
2.90 (d, J = 11.42 Hz, 2H), 3.44 (s, 2H), 4.17−4.34 (m, 1H),
7.03−7.13 (m, 3H), 7.17−7.24 (m, 1H), 7.66 (d, J = 1.17 Hz,
1H), 11.19 (br s, 1H). 13C NMR (75 MHz, DMSO-d6): δ
11.98, 21.00, 29.99 (2C), 52.40 (3C), 61.79, 108.91, 125.92,
127.55, 128.01, 129.38, 137.17, 137.70, 138.36, 150.82, 163.67.
HRMS (ESI): calcd for [C18H23N3O2 + H]
+, 314.1863; found,
314.1859.
5-Methyl-1-(1-(4-methylbenzyl)piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione (17). Following the General Procedure for
the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (131.8 mg, 0.40 mmol), 4-methylbenzal-
dehyde (96.1 mg, 0.80 mmol), and sodium triacetoxyborohy-
dride (169.6 mg, 0.80 mmol) in dry 1,2-dichloroethane (10
mL) using the ethyl acetate−hexane eluent system to obtain the
intermediate, which was dissolved with 80% TFA/H2O (28
mL), and the addition of L-cysteine hydrochloride (1.19 g, 7.59
mmol) to the reaction mixture yielded compound 17 (101.0
mg, 81%). 1H NMR (300 MHz, DMSO-d6): δ 1.62 (d, J = 9.37
Hz, 2H), 1.71−1.90 (m, 5H), 1.94−2.08 (m, 2H), 2.27 (s, 3H),
2.88 (d, J = 11.42 Hz, 2H), 3.42 (s, 2H), 4.24 (tt, J = 12.01,
3.66 Hz, 1H), 7.08−7.21 (m, 4H), 7.64 (d, J = 1.17 Hz, 1H),
11.18 (s, 1H). 13C NMR (75 MHz, DMSO-d6): δ 11.89, 20.59,
29.90 (2C), 52.19 (2C), 52.30, 61.38, 108.81, 128.61 (2C),
128.68 (2C), 135.22, 135.84, 137.60, 150.69, 163.56. HRMS
(ESI): calcd for [C18H23N3O2 + H]
+, 314.1863; found,
314.1869.
1-(1-(4-Methoxybenzyl)piperidin-4-yl)-5-methylpyrimi-
dine-2,4(1H,3H)-dione (18). Following the General Procedure
for the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (140.0 mg, 0.425 mmol), 4-methox-
ybenzaldehyde (115.7 mg, 0.85 mmol), and sodium triacetox-
yborohydride (180.2 mg, 0.85 mmol) in dry 1,2-dichloroethane
(10 mL) using the ethyl acetate−hexane eluent system to
obtain the intermediate, which was dissolved with 80% TFA/
H2O (36 mL), and the addition of L-cysteine hydrochloride
(1.53 g, 9.72 mmol) to the reaction mixture yielded compound
18 (99.4 mg, 71%). 1H NMR (300 MHz, DMSO-d6): δ 1.63
(d, J = 9.37 Hz, 2H), 1.73−1.91 (m, 5H), 1.94−2.07 (m, 2H),
2.89 (d, J = 11.42 Hz, 2H), 3.41 (s, 2H), 3.74 (s, 3H), 4.17−
4.33 (m, 1H), 6.84−6.92 (m, 2H), 7.17−7.25 (m, 2H), 7.64 (d,
J = 0.88 Hz, 1H), 11.19 (br s, 1H). 13C NMR (75 MHz,
DMSO-d6): δ 12.00, 29.99 (2C), 52.22 (2C), 52.43, 55.00,
61.15, 108.91, 113.51, 130.03 (2C), 130.22 (2C), 137.70,
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150.82, 158.27, 163.68. HRMS (ESI): calcd for [C18H23N3O3 +
H]+, 330.1812; found, 330.1806.
1-(1-(4-(Dimethylamino)benzyl)piperidin-4-yl)-5-methyl-
pyrimidine-2,4(1H,3H)-dione (19). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol), 4-
(dimethylamino)benzaldehyde (119.4 mg, 0.8 mmol), and
sodium triacetoxyborohydride (169.6 mg, 0.8 mmol) in dry 1,2-
dichloroethane (10 mL) using the ethyl acetate−hexane eluent
system to obtain the intermediate, which was dissolved with
80% TFA/H2O (33 mL), and the addition of L-cysteine
hydrochloride (1.40 g, 8.91 mmol) to the reaction mixture
yielded compound 19 (93.0 mg, 68%). 1H NMR (300 MHz,
DMSO-d6): δ 1.63 (d, J = 9.08 Hz, 2H), 1.71−1.89 (m, 5H),
1.91−2.05 (m, 2H), 2.80−2.95 (m, 8H), 3.35 (s, 2H), 4.24 (tt,
J = 11.97, 3.99 Hz, 1H), 6.67 (d, J = 8.79 Hz, 2H), 7.09 (d, J =
8.49 Hz, 2H), 7.64 (s, 1H), 11.18 (s, 1H). 13C NMR (75 MHz,
DMSO-d6): δ 12.00, 30.03 (2C), 40.25 (2C), 52.19 (2C),
52.50, 61.43, 108.90, 112.15 (2C), 125.63, 129.74 (2C), 137.72,
149.59, 150.82, 163.67. HRMS (ESI): calcd for [C19H26N4O2 +
H]+, 343.2129; found, 343.2118.
1-(1-(4-Chlorobenzyl)piperidin-4-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (20). Following the General Procedure for
the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol), 4-chlorobenzal-
dehyde (112.5 mg, 0.8 mmol), and sodium triacetoxyborohy-
dride (169.6 mg, 0.8 mmol) in dry 1,2-dichloroethane (10 mL)
using the ethyl acetate−hexane eluent system to obtain the
intermediate, which was dissolved with 80% TFA/H2O (30
mL), and the addition of L-cysteine hydrochloride (1.28 g, 8.10
mmol) to the reaction mixture yielded compound 20 (82.4 mg,
62%). 1H NMR (300 MHz, DMSO-d6): δ 1.65 (d, J = 9.67 Hz,
2H), 1.73−1.94 (m, 5H), 2.07 (t, J = 11.42 Hz, 2H), 2.89 (d, J
= 11.42 Hz, 2H), 3.49 (s, 2H), 4.26 (tt, J = 12.05, 3.77 Hz, 1H),
7.30−7.42 (m, 4H), 7.64 (d, J = 1.17 Hz, 1H), 11.20 (s, 1H).
13C NMR (75 MHz, DMSO-d6): δ 12.00, 29.95 (2C), 52.27
(2C), 52.31, 60.72, 108.93, 128.12 (2C), 130.54 (2C), 131.45,
137.54, 137.67, 150.80, 163.67. HRMS (ESI): calcd for
[C17H20ClN3O2 + H]
+, 334.1317; found, 334.1319.
1-(1-(3,4-Dichlorobenzyl)piperidin-4-yl)-5-methylpyrimi-
dine-2,4(1H,3H)-dione (21). Following the General Procedure
for the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol), 3,4-dichloroben-
zaldehyde (140.0 mg, 0.8 mmol), and sodium triacetoxybor-
ohydride (169.6 mg, 0.8 mmol) in dry 1,2-dichloroethane (10
mL) using the ethyl acetate−hexane eluent system to obtain the
intermediate, which was dissolved with 80% TFA/H2O (33
mL), and the addition of L-cysteine hydrochloride (1.40 g, 8.91
mmol) to the reaction mixture yielded compound 21 (94.4 mg,
64%). 1H NMR (300 MHz, DMSO-d6): δ 1.65 (d, J = 9.37 Hz,
2H), 1.74−1.96 (m, 5H), 2.01−2.16 (m, 2H), 2.89 (d, J =
11.42 Hz, 2H), 3.51 (s, 2H), 4.19−4.34 (m, 1H), 7.31 (dd, J =
8.20, 1.76 Hz, 1H), 7.55−7.62 (m, 2H), 7.66 (d, J = 0.88 Hz,
1H), 11.20 (s, 1H). 13C NMR (75 MHz, DMSO-d6): δ 12.03,
29.99 (2C), 52.30 (3C), 60.11, 108.99, 128.99, 129.41, 130.38,
130.42, 130.91, 137.73, 140.02, 150.85, 163.73. HRMS (ESI):
calcd for [C17H19Cl2N3O3 + H]
+, 368.0927; found, 368.0917.
4-((4-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-
piperidin-1yl)methyl) benzointrile (22). Following the General
Procedure for the Synthesis of Final Compounds (method 2),
3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol), 4-formylbenzoni-
trile (105.0 mg, 0.8 mmol), and sodium triacetoxyborohydride
(169.6 mg, 0.8 mmol) in dry 1,2-dichloroethane (10 mL) using
the ethyl acetate−hexane eluent system to obtain the
intermediate, which was dissolved with 80% TFA/H2O (30
mL), and the addition of L-cysteine hydrochloride (1.28 g, 8.10
mmol) to the reaction mixture yielded compound 22 (91.5 mg,
71%). 1H NMR (300 MHz, DMSO-d6): δ 1.65 (d, J = 9.37 Hz,
2H), 1.74−1.96 (m, 5H), 2.03−2.17 (m, 2H), 2.88 (d, J =
11.72 Hz, 2H), 3.59 (s, 2H), 4.27 (tt, J = 12.08, 3.88 Hz, 1H),
7.49−7.57 (m, 2H), 7.65 (d, J = 1.17 Hz, 1H), 7.77−7.84 (m,
2H), 11.19 (br s, 1H). 13C NMR (75 MHz, DMSO-d6): δ
12.00, 29.98 (2C), 52.24, 52.37 (2C), 60.95, 108.94, 109.71,
118.91, 129.48 (2C), 132.15 (2C), 137.66, 144.73, 150.83,
163.70. HRMS (ESI): calcd for [C18H20N4O2 + H]
+, 325.1659;
found, 325.1667.
4-((4-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-
piperidin-1-yl)methyl)benzoic acid (23). 4-((4-(5-Methyl-2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-yl)methyl)-
benzonitrile 22 (90.0 mg, 0.28 mg) was dissolved in 0.5 M
NaOH (11.1 mL) at room temperature. The reaction mixture
was heated at 90 °C for 3.5 h. After the mixture cooled to room
temperature, acetic acid (0.64 mL) was added to neutralize the
solution. After evaporation and drying with an oil pump, the
residue was puriﬁed with preparative HPLC to yield compound
23 (50.3 mg, 50%). 1H NMR (300 MHz, DMSO-d6): δ 1.65
(d, J = 9.37 Hz, 2H), 1.74−1.96 (m, 5H), 2.01−2.16 (m, 2H),
2.91 (d, J = 11.72 Hz, 2H), 3.56 (s, 2H), 4.27 (ddt, J = 11.94,
7.98, 3.95, 3.95 Hz, 1H), 7.42 (d, J = 8.49 Hz, 2H), 7.66 (d, J =
1.17 Hz, 1H), 7.91 (d, J = 8.20 Hz, 2H), 10.86−11.45 (m, 1H).
13C NMR (75 MHz, DMSO-d6): δ 11.98, 29.99 (2C) 52.30,
52.43 (2C), 61.30, 108.93, 128.61 (2C), 129.22 (2C), 130.45,
137.70, 143.35, 150.80, 163.67, 167.41. HRMS (ESI): calcd for
[C18H21N3O4 + H]
+, 343.1532; found, 343.1530.
1-(1-(4-(1H-Tetrazol-5-yl)benzyl)piperidin-4-yl)-5-methyl-
pyrimidine-2,4(1H,3H)-dione (24). According to the procedure
introduced by Hye Yeon Sagong,46 the compound 4-((4-(5-
methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)piperidin-1-
yl)methyl)benzonitrile 22 (103.4 mg, 0.319 mmol), NaN3
(82.9 mg, 1.275 mmol), and acetic acid (32 μL) in dry DMF
(5 mL) yielded the crude product, which was puriﬁed by
preparative HPLC to yield compound 24 (49.1 mg, 40%). 1H
NMR (300 MHz, DMSO-d6): δ 1.66−2.01 (m, 7H), 2.25 (t, J
= 10.98 Hz, 2H), 3.01 (d, J = 11.42 Hz, 2H), 3.69 (s, 2H), 4.31
(ddd, J = 11.94, 8.27, 3.81 Hz, 1H), 7.54 (d, J = 8.20 Hz, 2H),
7.63 (d, J = 0.88 Hz, 1H), 8.02 (d, J = 8.20 Hz, 2H), 11.22 (s,
1H). 13C NMR (75 MHz, DMSO-d6): δ 12.03, 29.49, 52.13
(3C), 60.75, 108.98, 124.56, 126.73 (2C), 129.83 (2C), 137.66,
140.02, 150.79, 156.04, 163.67. HRMS (ESI): calcd for
[C18H21N7O2 + H]
+, 368.1829; found, 368.1828.
5-Methyl-1-(1-(pyridin-2-ylmethyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (25). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol),
picolinaldehyde (85.7 mg, 0.8 mmol), and sodium triacetox-
yborohydride (169.6 mg, 0.8 mmol) in dry 1,2-dichloroethane
(10 mL) using the methanol−ethyl acetate eluent system to
obtain the intermediate, which was dissolved with 80% TFA/
H2O (22 mL), and the addition of L-cysteine hydrochloride
(0.94 g, 5.94 mmol) to the reaction mixture yielded compound
25 (57.2 mg, 48%). 1H NMR (300 MHz, D2O): δ 1.73−1.95
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(m, 7H), 2.27−2.44 (m, 2H), 3.09 (d, J = 12.30 Hz, 2H), 4.31−
4.47 (m, 1H), 7.41 (ddd, J = 7.62, 5.13, 1.03 Hz, 1H), 7.50 (d, J
= 7.91 Hz, 1H), 7.57 (d, J = 1.17 Hz, 1H), 7.89 (td, J = 7.76,
1.76 Hz, 1H), 8.50 (dt, J = 4.98, 0.88 Hz, 1H). 13C NMR (75
MHz, D2O): δ 12.07, 30.03 (2C), 52.76 (2C), 54.02, 63.26,
111.72, 124.13, 125.87, 138.82, 139.84, 149.02, 153.11, 155.99,
167.33. HRMS (ESI): calcd for [C16H20N4O2 + H]
+, 301.1659;
found, 301.1656.
5-Methyl-1-(1-(pyridin-3-ylmethyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (26). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (164.7 mg, 0.5 mmol),
nicotinaldehyde (107.1 mg, 1 mmol), and sodium triacetox-
yborohydride (212.0 mg, 1 mmol) in dry 1,2-dichloroethane
(15 mL) using the methanol−ethyl acetate eluent system to
obtain the intermediate, which was dissolved with 80% TFA/
H2O (32 mL), and the addition of L-cysteine hydrochloride
(1.36 g, 8.64 mmol) to the reaction mixture yielded compound
26 (61.4 mg, 41%). 1H NMR (300 MHz, DMSO-d6): δ 1.64
(d, J = 9.37 Hz, 2H), 1.72−1.93 (m, 5H), 2.00−2.15 (m, 2H),
2.89 (d, J = 11.72 Hz, 2H), 3.52 (s, 2H), 4.26 (tt, J = 12.05,
4.06 Hz, 1H), 7.36 (ddd, J = 7.76, 4.83, 0.88 Hz, 1H), 7.64 (d, J
= 1.17 Hz, 1H), 7.70 (dt, J = 7.76, 1.83 Hz, 1H), 8.47 (dd, J =
4.69, 1.76 Hz, 1H), 8.51 (d, J = 1.76 Hz, 1H), 10.46 (br s, 1H).
13C NMR (75 MHz, DMSO-d6): δ 12.03, 29.96 (2C), 52.27
(2C), 52.31, 58.81, 108.96, 123.40, 133.83, 136.53, 137.70,
148.31, 150.04, 150.85, 163.71. HRMS (ESI): calcd for
[C16H20N4O2 + H]
+, 301.1659; found, 301.1656.
5-Methyl-1-(1-(pyridin-4-ylmethyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (27). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol),
isonicotinaldehyde (85.7 mg, 0.8 mmol), and sodium
triacetoxyborohydride (169.6 mg, 0.8 mmol) in dry 1,2-
dichloroethane (10 mL) using the methanol−ethyl acetate
eluent system to obtain the intermediate, which was dissolved
with 80% TFA/H2O (30 mL), and the addition of L-cysteine
hydrochloride (1.28 g, 8.10 mmol) to the reaction mixture
yielded compound 27 (58.4 mg, 49%). 1H NMR (300 MHz,
DMSO-d6): δ 1.65 (d, J = 10.54 Hz, 2H), 1.72−1.99 (m, 5H),
1.99−2.21 (m, 2H), 2.88 (d, J = 11.13 Hz, 2H), 3.53 (s, 2H),
4.27 (t, J = 12.01 Hz, 1H), 7.33 (d, J = 5.27 Hz, 2H), 7.63 (s,
1H), 8.51 (d, J = 5.27 Hz, 2H). 13C NMR (75 MHz, DMSO-
d6): δ 12.06, 30.01 (2C), 52.28, 52.46 (2C), 60.30, 108.99,
123.72 (2C), 137.67, 147.72, 149.55 (2C), 150.92, 163.82.
HRMS (ESI): calcd for [C16H20N4O2 + H]
+, 301.1659; found,
301.1658.
6-((4-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-
piperidin-1-yl)methyl)picolinic Acid (28). According to a
literature procedure,47 the suspension of methyl 6-
(hydroxymethyl)picolinate (0.42 g, 2.50 mmol) and
manganese(IV) dioxide (4.35 g, 50.00 mmol) in CH2Cl2 (20
mL) was stirred at room temperature for 3 h. After ﬁltration
with Celite, the ﬁltrate was evaporated under reduced pressure,
and the residue was puriﬁed by column chromatography (100%
hexane−30% ethyl acetate/hexane in a linear gradient elution)
to oﬀer methyl 3-formylbenzoate as a colorless gel (255.8 mg,
62%). 1H NMR (300 MHz, CDCl3): δ 4.07 (s, 3H), 8.06 (td, J
= 7.76, 0.88 Hz, 1H), 8.13−8.18 (m, 1H), 8.36 (dd, J = 7.62,
1.17 Hz, 1H), 10.19 (d, J = 0.88 Hz, 1H). HRMS (ESI): calcd
for [C8H7NO3 + H]
+, 166.0499; found, 166.0482.
Following the General Procedure for the Synthesis of Final
Compounds (method 2), 3-((benzyloxy)methyl)-5-methyl-1-
(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione 63 (88.4 mg,
0.268 mmol), methyl 3-formylbenzoate (66.6 mg, 0.403
mmol), and sodium triacetoxyborohydride (113.6 mg, 0.536
mmol) in dry 1,2-dichloroethane (6 mL) using the ethyl
acetate−methanol eluent system obtained the picolinate
intermediate, which was dissolved in THF (8 mL). NaOH
(53.6 mg, 2.68 mmol) in H2O (4 mL) was added to the
reaction mixture at room temperature. The solution was stirred
at room temperature for 1 h. Two M HCl was used to
neutralize the pH to 3. After extraction with CH2Cl2 (20 mL ×
5), the combined organic layer was concentrated to oﬀer the
picolinic acid intermediate, which was dissolved with 80%
TFA/H2O (30 mL), and L-cysteine hydrochloride (1.28 g, 8.1
mmol) was added to the reaction mixture to yield compound
28 (54.8 mg, 51%). 1H NMR (300 MHz, D2O): δ 1.79 (s, 3H),
2.01−2.32 (m, 4H), 3.28 (t, J = 11.72 Hz, 2H), 3.61 (d, J =
12.30 Hz, 2H), 4.46 (s, 2H), 4.56−4.65 (m, 1H), 7.43 (s, 1H),
7.50 (dd, J = 5.57, 2.34 Hz, 1H), 7.87−7.96 (m, 2H). 13C NMR
(75 MHz, D2O): δ 10.64, 26.15 (2C), 50.30, 51.46 (2C), 59.38,
110.64, 123.46, 125.26, 137.92, 138.67, 147.95, 151.31, 152.21,
165.65, 171.38. HRMS (ESI): calcd for [C17H20N4O4 + H]
+,
345.1557; found, 345.1554.
1-(1-(Furan-2-ylmethyl)piperidin-4-yl)-5-methylpyrimi-
dine-2,4(1H,3H)-dione (29). Following the General Procedure
for the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (140.0 mg, 0.425 mmol), furan-2-
carbaldehyde (81.7 mg, 0.85 mmol), and sodium triacetox-
yborohydride (180.2 mg, 0.85 mmol) in dry 1,2-dichloroethane
(10 mL) using the ethyl acetate−hexane eluent system to
obtain the intermediate, which was dissolved with 80% TFA/
H2O (30 mL), and the addition of L-cysteine hydrochloride
(1.28 g, 8.10 mmol) to the reaction mixture yielded compound
29 (84.0 mg, 68%). 1H NMR (300 MHz, DMSO-d6): δ 1.64
(dd, J = 11.57, 2.20 Hz, 1H), 1.74−1.92 (m, 5H), 2.02−2.13
(m, 1H), 2.92 (d, J = 11.72 Hz, 2H), 3.51 (s, 2H), 4.23 (tt, J =
12.12, 3.99 Hz, 1H), 6.28 (dd, J = 3.08, 0.73 Hz, 1H), 6.40 (dd,
J = 3.22, 1.76 Hz, 1H), 7.58 (dd, J = 2.05, 0.88 Hz, 1H), 7.64
(d, J = 1.17 Hz, 1H), 11.19 (s, 1H). 13C NMR (75 MHz,
DMSO-d6): δ 12.03, 29.87 (2C), 51.99 (2C), 52.21, 53.67,
108.58, 108.93, 110.29, 137.72, 142.33, 150.82, 151.93, 163.68.
HRMS (ESI): calcd for [C15H19N3O3 + H]
+, 290.1499; found,
290.1495.
1-(1-(Furan-3-ylmethyl)piperidin-4-yl)-5-methylpyrimi-
dine-2,4(1H,3H)-dione (30). Following the General Procedure
for the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol), furan-3-
carbaldehyde (76.9 mg, 0.8 mmol), and sodium triacetoxybor-
ohydride (169.6 mg, 0.8 mmol) in dry 1,2-dichloroethane (10
mL) using the ethyl acetate−hexane eluent system to obtain the
intermediate, which was dissolved with 80% TFA/H2O (25
mL), and the addition of L-cysteine hydrochloride (1.06 g, 6.75
mmol) to the reaction mixture yielded compound 30 (63.1 mg,
55%). 1H NMR (300 MHz, DMSO-d6): δ 1.57−1.70 (m, 2H),
1.73−1.92 (m, 5H), 1.94−2.07 (m, 2H), 2.93 (d, J = 11.72 Hz,
2H), 3.34 (s, 2H), 4.16−4.30 (m, 1H), 6.41 (dd, J = 1.76, 0.59
Hz, 1H), 7.56 (d, J = 0.88 Hz, 1H), 7.61 (t, J = 1.61 Hz, 1H),
7.62−7.65 (m, 1H), 7.63 (d, J = 1.17 Hz, 1H), 8.62−9.54 (m,
1H). 13C NMR (75 MHz, DMSO-d6): δ 12.01, 29.93 (2C),
51.79, 52.13 (2C), 52.40, 108.90, 111.45, 121.68, 137.70,
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140.89, 143.28, 150.82, 163.67. HRMS (ESI): calcd for
[C15H19N3O3 + H]
+, 290.1499; found, 290.1494.
5-Methyl-1-(1-(1-phenylethyl)piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione (31). According to a modiﬁed literature
procedure,48 a mixture of 3-((benzyloxy)methyl)-5-methyl-1-
(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione 63 (148.2 mg,
0.45 mmol) and acetophenone (64.9 mg, 0.54 mmol) in dry
THF (5 mL) at room temperature was treated with Ti(Oi-Pr)4
(255.8 mg, 0.9 mmol) under argon. The reaction mixture was
heated at 75 °C overnight. After the mixture cooled to room
temperature, NaBH4 (68.95 mg, 1.35 mmol) was added to the
reaction mixture, and it was stirred further at room temperature
for 24 h, followed by dilution with CH2Cl2 (20 mL) and
ﬁltration. The ﬁltrate was evaporated and puriﬁed by column
chromatography (0.8% Et3N/10% ethyl acetate/hexane−0.8%
Et3N/50% ethyl acetate/hexane) to oﬀer the intermediate as a
yellow gel (160.0 mg, 82%), which followed the general BOM-
deprotecting procedure. (See the General Procedure for the
Synthesis of Final Compounds, method 2.) The obtained
intermediate was dissolved with 80% TFA/H2O (32 mL), and
L-cysteine hydrochloride (1.36 g, 8.64 mmol) was added to the
reaction mixture to oﬀer compound 31 (92.5 mg, 80%). 1H
NMR (300 MHz, DMSO-d6): δ 1.30 (d, J = 6.74 Hz, 3H),
1.55−2.07 (m, 9H), 2.85 (dd, J = 11.13, 1.76 Hz, 1H), 3.06 (d,
J = 10.84 Hz, 1H), 3.51 (q, J = 6.74 Hz, 1H), 4.08−4.25 (m,
1H), 7.19−7.28 (m, 1H), 7.29−7.37 (m, 4H), 7.64 (d, J = 0.88
Hz, 1H), 11.17 (s, 1H). 13C NMR (75 MHz, DMSO-d6): δ
11.98, 18.94, 30.21, 30.25, 49.00, 49.58, 52.59 (s, 1C), 63.09,
108.90, 126.77, 127.34 (2C), 128.09 (2C), 137.70, 143.41,
150.80, 163.67. HRMS (ESI): calcd for [C18H23N3O2 + H]
+,
314.1863; found, 314.1861.
1-(1-(Cyclohexylmethyl)piperidin-4-yl)-5-methylpyrimi-
dine-2,4(1H,3H)-dione (32). Following the General Procedure
for the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (167.6 mg, 0.5 mmol), cyclohexanecar-
baldehyde (112.2 mg, 1 mmol), and sodium triacetoxyborohy-
dride (212.0 mg, 1 mmol) in dry 1,2-dichloroethane (10 mL)
using the ethyl acetate−hexane eluent system to obtain the
intermediate, which was dissolved with 80% TFA/H2O (32
mL), and the addition of L-cysteine hydrochloride (1.36 g, 8.64
mmol) to the reaction mixture yielded compound 32 (90.0 mg,
59%). 1H NMR (300 MHz, DMSO-d6): δ 0.73−0.91 (m, 2H),
1.07−1.29 (m, 3H), 1.36−1.53 (m, 1H), 1.56−1.99 (m, 14 H),
2.02−2.14 (m, 2H), 2.89 (d, J = 11.13 Hz, 2H), 4.22 (tt, J =
11.64, 3.88 Hz, 1H), 7.63 (d, J = 1.17 Hz, 1H), 11.17 (s, 1H).
13C NMR (75 MHz, DMSO-d6): δ 11.97, 25.54 (2C), 26.39,
30.15 (2C), 31.28 (2C), 34.83, 52.54, 53.04 (2C), 64.46,
108.91, 137.69, 150.82, 163.67. HRMS (ESI): calcd for
[C17H27N3O2 + H]
+, 306.2176; found, 306.2155.
5-Methyl-1-(1-(naphthalen-1-ylmethyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (33). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (164.7 mg, 0.5 mmol), 1-
naphthaldehyde (156.2 mg, 1 mmol), and sodium triacetox-
yborohydride (212.0 mg, 1 mmol) in dry 1,2-dichloroethane
(10 mL) using the ethyl acetate−hexane eluent system to
obtain the intermediate, which was dissolved with 80% TFA/
H2O (30 mL), and the addition of L-cysteine hydrochloride
(1.28 g, 8.10 mmol) to the reaction mixture yielded compound
33 (85.0 mg, 49%). 1H NMR (300 MHz, DMSO-d6): δ 1.57−
1.69 (m, 2H), 1.70−1.89 (m, 5H), 2.07−2.22 (m, 2H), 2.99 (d,
J = 11.72 Hz, 2H), 3.89 (s, 2H), 4.28 (tt, J = 12.05, 3.77 Hz,
1H), 7.40−7.47 (m, 2H), 7.47−7.58 (m, 2H), 7.60 (d, J = 0.88
Hz, 1H), 7.79−7.87 (m, 1H), 7.87−7.95 (m, 1H), 8.25 (dd, J =
8.49, 1.17 Hz, 1H), 11.18 (s, 1H). 13C NMR (75 MHz, DMSO-
d6): δ 11.94, 30.06 (2C), 52.56, 52.71 (2C), 59.85, 108.90,
124.77, 125.17, 125.63, 125.81, 127.35, 127.72, 128.24, 132.03,
133.46, 134.16, 137.69, 150.82, 163.67. HRMS (ESI): calcd for
[C21H23N3O2 + H]
+, 350.1863; found, 350.1864.
5-Methyl-1-(1-(naphthalen-2-ylmethyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (34). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol), 2-
naphthaldehyde (124.9 mg, 0.8 mmol), and sodium triacetox-
yborohydride (169.6 mg, 0.8 mmol) in dry 1,2-dichloroethane
(10 mL) using the ethyl acetate−hexane eluent system to
obtain the intermediate, which was dissolved with 80% TFA/
H2O (32 mL), and the addition of L-cysteine hydrochloride
(1.36 g, 8.64 mmol) to the reaction mixture yielded compound
34 (100.0 mg, 72%). 1H NMR (300 MHz, DMSO-d6): δ 1.66
(d, J = 9.67 Hz, 2H), 1.75−1.98 (m, 5H), 2.03−2.19 (m, 2H),
2.96 (d, J = 11.72 Hz, 2H), 3.65 (s, 2H), 4.29 (tt, J = 12.01,
3.95 Hz, 1H), 7.44−7.55 (m, 3H), 7.67 (d, J = 1.17 Hz, 1H),
7.80 (s, 1H), 7.85−7.93 (m, 3H), 11.20 (s, 1H). 13C NMR (75
MHz, DMSO-d6): δ 12.00, 30.03 (2C), 52.42, 52.48 (2C),
61.87, 108.93, 125.63 (2C), 126.06, 127.09, 127.28, 127.51,
127.66, 132.27, 132.86, 136.22, 137.70, 150.82, 163.67. HRMS
(ESI): calcd for [C21H23N3O2 + H]
+, 350.1863; found,
350.1862.
5-Methyl-1-(1-(quinolin-2-ylmethyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (35). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol),
quinoline-2-carbaldehyde (125.7 mg, 0.8 mmol), and sodium
triacetoxyborohydride (169.6 mg, 0.8 mmol) in dry 1,2-
dichloroethane (10 mL) using the methanol−ethyl acetate
eluent system to obtain the intermediate, which was dissolved
with 80% TFA/H2O (36 mL), and the addition of L-cysteine
hydrochloride (1.53 g, 9.72 mmol) to the reaction mixture
yielded compound 35 (85.3 mg, 61%). 1H NMR (300 MHz,
DMSO-d6): δ 1.60−1.71 (m, 2H), 1.73−2.00 (m, 5H), 2.14−
2.30 (m, 2H), 2.95 (d, J = 11.42 Hz, 2H), 3.79 (s, 2H), 4.30 (tt,
J = 12.19, 4.06 Hz, 1H), 7.53−7.61 (m, 1H), 7.62−7.69 (m,
2H), 7.73 (ddd, J = 8.49, 6.88, 1.32 Hz, 1H), 7.91−8.01 (m,
2H), 8.34 (d, J = 8.20 Hz, 1H), 11.20 (br s, 1H). 13C NMR (75
MHz, DMSO-d6): δ 12.01, 30.04, 52.28, 52.75 (2C), 64.00,
108.94, 121.00, 126.16, 126.97, 127.80, 128.53, 129.46, 136.31,
137.70, 147.00, 150.83, 159.64, 163.70. HRMS (ESI): calcd for
[C20H22N4O2 + H]
+, 351.1816; found, 351.1825.
5-Methyl-1-(1-(quinolin-3-ylmethyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (36). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (98.8 mg, 0.3 mmol), quino-
line-3-carbaldehyde (94.3 mg, 0.6 mmol), and sodium
triacetoxyborohydride (127.2 mg, 0.6 mmol) in dry 1,2-
dichloroethane (8 mL) using the ethyl acetate−methanol
eluent system to obtain the intermediate, which was dissolved
with 80% TFA/H2O (30 mL), and the addition of L-cysteine
hydrochloride (1.28 g, 8.1 mmol) to the reaction mixture
yielded compound 36 (46.7 mg, 44%). 1H NMR (300 MHz,
DMSO-d6): δ 1.67 (d, J = 9.37 Hz, 2H), 1.74−1.97 (m, 5H),
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2.08−2.23 (m, 2H), 2.97 (d, J = 11.42 Hz, 2H), 3.72 (s, 2H),
4.21−4.37 (m, 1H), 7.58−7.64 (m, 1H), 7.66 (d, J = 1.17 Hz,
1H), 7.74 (m, 1H), 7.97 (dd, J = 8.20, 1.17 Hz, 1H), 8.02 (d, J
= 8.49 Hz, 1H), 8.22 (d, J = 1.76 Hz, 1H), 8.88 (d, J = 2.05 Hz,
1H), 11.19 (s, 1H). 13C NMR (75 MHz, DMSO-d6): δ 12.00,
29.96 (2C), 52.36 (3C), 59.06, 108.91, 126.68, 127.45, 127.83,
128.67, 129.11, 131.38, 135.12, 137.69, 146.92, 150.80, 151.98,
163.65. HRMS (ESI): calcd for [C20H22N4O2 + H]
+, 351.1816;
found, 351.1826.
5-Methyl-1-(1-(quinolin-4-ylmethyl)piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (37). Following the General
Procedure for the Synthesis of Final Compounds (method
2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione 63 (92.2 mg, 0.28 mmol),
isoquinoline-4-carbaldehyde (88.0 mg, 0.56 mmol), and sodium
triacetoxyborohydride (118.7 mg, 0.56 mmol) in dry 1,2-
dichloroethane (8 mL) using the ethyl acetate−hexane eluent
system to obtain the intermediate, which was dissolved with
80% TFA/H2O (30 mL), and the addition of L-cysteine
hydrochloride (1.28 g, 8.1 mmol) to the reaction mixture
yielded compound 37 (51.0 mg, 52%). 1H NMR (300 MHz,
DMSO-d6): δ 1.67 (d, J = 9.67 Hz, 2H), 1.73−1.95 (m, 5H),
2.17−2.30 (m, 2H), 3.00 (d, J = 11.42 Hz, 2H), 3.98 (s, 2H),
4.23−4.40 (m, 1H), 7.52 (d, J = 4.39 Hz, 1H), 7.59−7.68 (m,
2H), 7.77 (m, 1H), 8.04 (dd, J = 8.20, 0.88 Hz, 1H), 8.29 (dd, J
= 8.49, 0.88 Hz, 1H), 8.86 (d, J = 4.39 Hz, 1H), 11.21 (s, 1H).
13C NMR (75 MHz, DMSO-d6): δ 11.95, 30.03 (2C), 52.37,
52.79 (2C), 58.10, 108.91, 121.42, 124.61, 126.32, 127.13,
129.12, 129.43, 137.66, 143.95, 147.90, 150.14, 150.82, 163.67.
HRMS (ESI): calcd for [C20H22N4O2 + H]
+, 351.1816; found,
351.1807.
1-(1-(Isoquinolin-1-ylmethyl)piperidin-4-yl)-5-methylpyri-
midine-2,4(1H,3H)-diimine (38). According to a literature
procedure,49 the suspension of 1-methylisoquinoline (286.4
mg, 2 mmol) and SeO2 (443.8 mg, 4 mmol) in 1,4-dioxane (10
mL) was heated at 80 °C for 2 h. After cooling to room
temperature, the reaction mixture was ﬁltered through Celite.
The ﬁltrate was evaporated and puriﬁed with column
chromatography (100% hexane−10% ethyl acetate/hexane) to
oﬀer compound isoquinoline-1-carbaldehyde as a white solid
(220.0 mg, 70%). 1H NMR (300 MHz, CDCl3): δ 7.73−7.80
(m, 2H), 7.88−7.95 (m, 2H), 8.77 (d, J = 5.57 Hz, 1H), 9.30−
9.37 (m, 1H), 10.38−10.42 (m, 1H). HRMS (ESI): calcd for
[C10H7NO + H]
+, 158.0600; found, 158.0604.
Following the General Procedure for the Synthesis of Final
Compounds (method 2), 3-((benzyloxy)methyl)-5-methyl-1-
(piperidin-4-yl)pyrimidine-2,4(1H,3H)-dione 63 (82.3 mg,
0.25 mmol), isoquinoline-1-carbaldehyde (78.6 mg, 0.5
mmol), and sodium triacetoxyborohydride (106.0 mg, 0.5
mmol) in dry 1,2-dichloroethane (5 mL) using the ethyl
acetate−methanol eluent system to obtain the intermediate,
which was dissolved with 80% TFA/H2O (30 mL), and the
addition of L-cysteine hydrochloride (1.28 g, 8.1 mmol) to the
reaction mixture yielded compound 38 (37.7 mg, 43%). 1H
NMR (300 MHz, DMSO-d6): δ 1.58−1.86 (m, 7H), 2.14−2.31
(m, 2H), 3.01 (d, J = 11.72 Hz, 2H), 4.07 (s, 2H), 4.21−4.36
(m, 1H), 7.59 (d, J = 1.17 Hz, 1H), 7.65−7.73 (m, 1H), 7.74−
7.81 (m, 2H), 7.96 (d, J = 7.91 Hz, 1H), 8.41 (d, J = 5.86 Hz,
1H), 8.48 (d, J = 7.91 Hz, 1H), 11.19 (s, 1H). 13C NMR (75
MHz, DMSO-d6): δ 11.89, 30.01 (2C), 52.43, 52.85 (2C),
62.28, 108.87, 120.41, 126.44, 126.96, 127.08, 127.16, 130.10,
135.86, 137.67, 141.25, 150.80, 157.81, 163.64. HRMS (ESI):
calcd for [C20H22N4O2 + H]
+, 351.1816; found 351.1823.
1-(1-(Isoquinolin-3-ylmethyl)piperidin-4-yl)-5-methylpyri-
midine-2,4(1H,3H)-dione (39). Following the General Proce-
dure for the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (92.2 mg, 0.28 mmol), isoquinoline-3-
carbaldehyde (88.0 mg, 0.56 mmol), and sodium triacetox-
yborohydride (118.7 mg, 0.56 mmol) in dry 1,2-dichloroethane
(8 mL) using the ethyl acetate−hexane eluent system to obtain
the intermediate, which was dissolved with 80% TFA/H2O (30
mL), and the addition of L-cysteine hydrochloride (1.28 g, 8.1
mmol) to the reaction mixture yielded compound 39 (44.2 mg,
45%). 1H NMR (300 MHz, DMSO-d6): δ 1.67 (d, J = 9.37 Hz,
2H), 1.75−2.03 (m, 5H), 2.21 (t, J = 10.98 Hz, 2H), 3.03 (d, J
= 11.72 Hz, 2H), 3.79 (s, 2H), 4.22−4.38 (m, 1H), 7.60−7.70
(m, 2H), 7.73−7.84 (m, 2H), 7.91−7.98 (m, 1H), 8.11 (d, J =
7.91 Hz, 1H), 9.27 (s, 1H), 11.20 (s, 1H). 13C NMR (75 MHz,
DMSO-d6): δ 12.01, 30.06 (2C), 52.39, 52.60 (2C), 63.24,
108.91, 118.36, 126.32, 126.99, 127.23, 127.46, 130.56, 135.67,
137.72, 150.82, 151.76, 151.90, 163.67. HRMS (ESI): calcd for
[C20H22N4O2 + H]
+, 351.1816; found 351.1829.
1-(1-(Isoquinolin-4-ylmethyl)piperidin-4-yl)-5-methylpyri-
midine-2,4(1H,3H)-dione (40). Following the General Proce-
dure for the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (92.2 mg, 0.28 mmol), isoquinoline-4-
carbaldehyde (88.0 mg, 0.56 mmol), and sodium triacetox-
yborohydride (118.7 mg, 0.56 mmol) in dry 1,2-dichloroethane
(8 mL) using the ethyl acetate−hexane eluent system to obtain
the intermediate, which was dissolved with 80% TFA/H2O (30
mL), and the addition of L-cysteine hydrochloride (1.28 g, 8.1
mmol) to the reaction mixture yielded compound 40 (49.1 mg,
50%). 1H NMR (300 MHz, DMSO-d6): δ 1.65 (d, J = 9.00 Hz,
2H), 1.71−1.89 (m, 5H), 2.18 (t, J = 10.84 Hz, 2H), 3.00 (d, J
= 11.42 Hz, 2H), 3.89 (s, 2H), 4.21−4.38 (m, 1H), 7.61 (s,
1H), 7.66−7.74 (m, 1H), 7.78−7.87 (m, 1H), 8.14 (d, J = 8.20
Hz, 1H), 8.29 (d, J = 8.49 Hz, 1H), 8.42 (s, 1H), 9.25 (s, 1H),
11.19 (br s, 1H). 13C NMR (75 MHz, DMSO-d6): δ 11.92,
29.99 (2C), 52.48, 52.60 (2C), 56.88, 108.87, 124.00, 127.19,
127.92, 128.09, 130.38, 134.57, 137.67, 143.41, 150.80, 152.43,
163.65. HRMS (ESI): calcd for [C20H22N4O2 + H]
+, 351.1816;
found, 351.1817.
1-(1-(Benzofuran-2-ylmethyl)piperidin-4-yl)-5-methylpyri-
midine-2,4(1H,3H)-dione (41). Following the General Proce-
dure for the Synthesis of Final Compounds (method 2), 3-
((benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)pyrimidine-
2,4(1H,3H)-dione 63 (131.8 mg, 0.4 mmol), benzofuran-2-
carbaldehyde (116.9 mg, 0.8 mmol), and sodium triacetox-
yborohydride (169.6 mg, 0.8 mmol) in dry 1,2-dichloroethane
(10 mL) using the ethyl acetate−hexane eluent system to
obtain the intermediate, which was dissolved with 80% TFA/
H2O (33 mL), and the addition of L-cysteine hydrochloride
(1.40 g, 8.91 mmol) to the reaction mixture yielded compound
41 (120.0 mg, 88%). 1H NMR (300 MHz, DMSO-d6): δ 1.66
(d, J = 9.67 Hz, 2H), 1.76 (d, J = 1.17 Hz, 3H), 1.88 (qd, J =
12.16, 3.66 Hz, 2H), 2.09−2.25 (m, 2H), 3.00 (d, J = 11.72 Hz,
2H), 3.70 (s, 2H), 4.26 (ddd, J = 12.16, 8.20, 3.95 Hz, 1H),
6.78 (d, J = 0.88 Hz, 1H), 7.17−7.31 (m, 2H), 7.51−7.62 (m,
2H), 7.66 (d, J = 1.17 Hz, 1H), 10.46 (br s, 1H). 13C NMR (75
MHz, DMSO-d6): δ 11.92, 29.80 (2C), 52.04, 52.11 (2C),
53.99, 105.22, 108.81, 110.82, 120.73, 122.61, 123.83, 127.89,
137.64, 150.69, 154.22, 155.14, 163.56. HRMS (ESI): calcd for
[C19H21N3O3 + H]
+, 340.1656; found, 340.1661.
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5-Methyl-1-(1-((4-phenoxyquinolin-2-yl)methyl)piperidin-
4-yl)pyrimidine-2,4(1H,3H)-dione (42). Following the General
Procedure for the Synthesis of Final Compounds (method 2),
the suspension of 3-((benzyloxy)methyl)-5-methyl-1-(piper-
idin-4-yl)pyrimidine-2,4(1H,3H)-dione 63 (114.5 mg, 0.35
mmol), 4-phenoxyquinoline-2-carbaldehyde 55 (130.0 mg,
0.52 mmol), and sodium triacetoxyborohydride (259.7 mg,
1.23 mmol) in dry 1,2-dichloroethane (5 mL) was stirred at
room temperature for 48 h (ethyl acetate−hexane eluent
system) to give the intermediate, which was dissolved with 80%
TFA/H2O (30 mL), and the addition of L-cysteine hydro-
chloride (1.28 g, 8.1 mmol) to the reaction mixture yielded
compound 42 (75.6 mg, 49%). 1H NMR (300 MHz, DMSO-
d6): δ 1.52−1.85 (m, 7H), 2.09−2.23 (m, 2H), 2.88 (d, J =
11.42 Hz, 2H), 3.69 (s, 2H), 4.17−4.32 (m, 1H), 6.83 (s, 1H),
7.27−7.39 (m, 3H), 7.49−7.67 (m, 4H), 7.81 (m, 1H), 8.00 (d,
J = 8.20 Hz, 1H), 8.26 (dd, J = 8.35, 1.03 Hz, 1H), 11.20 (s,
1H). 13C NMR (75 MHz, DMSO-d6): δ 12.03, 29.86 (2C),
52.33, 52.53 (2C), 63.93, 104.12, 108.90, 120.15, 120.55 (2C),
121.35, 125.49, 126.07, 128.51, 130.30, 130.54 (2C), 137.54,
148.65, 150.77, 154.33, 160.77, 161.04, 163.64. HRMS (ESI):
calcd for [C26H26N4O3 + H]
+, 443.2078; found, 443.2071.
1-(1-((4-(3-Chlorophenoxy)quinolin-2-yl)methyl)piperidin-
4-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (43). Following
the General Procedure for the Synthesis of Final Compounds
(method 2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-
yl)pyrimidine-2,4(1H,3H)-dione 63 (82.3 mg, 0.25 mmol), 4-
(3-chlorophenoxy)quinoline-2-carbaldehyde 57 (141.9 mg, 0.5
mmol), and sodium triacetoxyborohydride (106.0 mg, 0.5
mmol) in dry 1,2-dichloroethane (10 mL) using the ethyl
acetate−methanol eluent system to obtain the intermediate,
which was dissolved with 80% TFA/H2O (30 mL), and the
addition of L-cysteine hydrochloride (1.28 g, 8.1 mmol) to the
reaction mixture yielded compound 43 (32.3 mg, 27%). 1H
NMR (300 MHz, DMSO-d6): δ 1.55−1.89 (m, 7H), 2.16 (t, J
= 10.84 Hz, 2H), 2.91 (d, J = 11.72 Hz, 2H), 3.72 (s, 2H),
4.19−4.33 (m, 1H), 6.92 (s, 1H), 7.29 (ddd, J = 8.20, 2.34, 0.88
Hz, 1H), 7.42 (ddd, J = 7.98, 1.98, 0.88 Hz, 1H), 7.46−7.67 (m,
4H), 7.78−7.85 (m, 1 H) 8.01 (d, J = 7.91 Hz, 1H), 8.21 (dd, J
= 8.35, 1.03 Hz, 1H), 11.21 (s, 1H). 13C NMR (75 MHz,
DMSO-d6): δ 12.06, 29.96 (2C), 52.21, 52.48 (2C), 63.75,
104.69, 108.90, 119.16, 120.09, 120.65, 121.29, 125.48, 126.22,
128.54, 130.41, 131.93, 134.27, 137.43, 148.72, 150.76, 155.35,
160.40, 160.95, 163.62. HRMS (ESI): calcd for [C26H25ClN4O3
+ H]+, 477.1688; found, 477.1682.
1-(1-((7-Chloro-4-phenoxyquinolin-2-yl)methyl)piperidin-
4-yl)-5-methylpyrimidine-2,4 (1H,3H)-dione (44). Following
the General Procedure for the Synthesis of Final Compounds
(method 2), 3-((benzyloxy)methyl)-5-methyl-1-(piperidin-4-
yl)pyrimidine-2,4(1H,3H)-dione 63 (90.0 mg, 0.273 mmol),
7-chloro-4-phenoxyquinoline-2-carbaldehyde 60 (120.0 mg,
0.423 mmol), and sodium triacetoxyborohydride (115.7 mg,
0.546 mmol) in dry 1,2-dichloroethane (8 mL) using the ethyl
acetate−hexane eluent system to obtain the intermediate, which
was dissolved with 80% TFA/H2O (32 mL), and the addition
of L-cysteine hydrochloride (1.40 g, 8.88 mmol) to the reaction
mixture yielded compound 44 (54.0 mg, 41%). 1H NMR (300
MHz, pyridine-d5): δ 1.73−1.89 (m, 4H), 2.03 (d, J = 0.88 Hz,
3H), 2.14 (td, J = 11.50, 2.78 Hz, 2H), 2.89 (d, J = 11.72 Hz,
2H), 3.79 (s, 2H), 4.60−4.75 (m, 1H), 7.14 (s, 1H), 7.24−7.37
(m, 4H), 7.44−7.52 (m, 2H), 7.62 (dd, J = 8.79, 2.05 Hz, 1H),
8.31−8.38 (m, 2H), 13.18 (br s, 1H). 13C NMR (75 MHz,
pyridine-d5): δ 13.14, 31.26 (2C), 53.21, 53.51 (2C), 65.25,
105.29, 110.64, 120.19, 121.46 (2C), 124.34, 126.28, 127.23,
128.75, 131.18 (2C), 136.40, 137.23, 150.71, 152.46, 155.38 (s,
1C), 162.54, 163.59, 165.13. HRMS (ESI): calcd for
[C26H25ClN4O3 + H]
+, 477.1688; found, 477.1690.
Methyl 2-(3-Phenoxyphenyl)acetate (49). According to a
literature procedure,50 to the solution of 2-(3-hydroxyphenyl)-
acetic acid 45 (5.08 g, 33.4 mmol) in MeOH (20 mL) was
added concentrated H2SO4 (0.5 mL) to oﬀer the desired
intermediate methyl 2-(3-hydroxyphenyl)acetate 46 (4.94 g,
89%). According to a literature procedure,51 compound 46
(0.53 g, 3.2 mmol), phenylboronic acid (1.17 g, 9.6 mmol),
Cu(OAc)2 (1.16 g, 6.4 mmol), molecular sieves (0.60 g), and
pyridine (0.77 mL, 9.6 mmol) in 1,2-dichloroethane (10 mL)
yielded compound 49 as a colorless gel (0.25 g, 33%). 1H NMR
(300 MHz, CDCl3): δ 3.60 (s, 2H), 3.69 (s, 3H), 6.88−6.93
(m, 1H), 6.93−6.96 (m, 1H), 6.99−7.04 (m, 3H), 7.11 (tt, J =
7.32, 1.17 Hz, 1H), 7.24−7.28 (m, 1H), 7.30−7.37 (m, 2H).
HRMS (ESI): calcd for [C15H14O3 + H]
+, 243.1016; found,
243.1024.
2-(3-Phenoxyphenyl)acetaldehyde (50). According to a
literature procedure,47 methyl 2-(3-phenoxyphenyl)acetate 49
(0.73 g, 3.01 mmol) was reduced by LiAlH4 (285.4 mg, 7.52
mmol) in dry THF (20 mL) to oﬀer the alcohol, which was
dissolved with dry CH2Cl2 (8 mL). Dess−Martin reagent (1.53
g, 3.61 mmol) was added to the reaction mixture at 0 °C under
argon. The reaction mixture was stirred at room temperature
for 8 h, followed by dilution with CH2Cl2 (100 mL), and
washed with the mixture of a saturated Na2S2O3 solution (50
mL) and saturated NaHCO3 solution (50 mL) and brine (100
mL) sequentially. The organic layer was dried over Na2SO4 and
puriﬁed with column chromatography (100% hexane−10%
ethyl acetate/hexane in a linear gradient solution) to oﬀer
compound 50 (0.36 g, 56%) as a colorless oil. 1H NMR (300
MHz, CDCl3): δ 3.66 (d, J = 2.34 Hz, 2H), 6.86−6.89 (m, 1H),
6.91−6.97 (m, 2H), 7.00−7.05 (m, 2H), 7.13 (tt, J = 7.43, 1.06
Hz, 1H), 7.31−7.39 (m, 3H), 9.74 (t, J = 2.20 Hz, 1H). HRMS
(ESI): calcd for [C14H12O2 + H]
+, 213.0910; found, 213.0904.
Methyl 3-(3-Phenoxyphenyl)propanoate (51). According
to a literature procedure,50 to the solution of 3-Hydroxycin-
namic acid 47 (11.49 g, 70 mmol) in MeOH (40 mL) was
added concentrated H2SO4 (1.15 mL) to oﬀer compound
methyl 3-(3-hydroxyphenyl)acrylate as a white solid. 1H NMR
(300 MHz, CDCl3): δ 3.82 (s, 3H), 6.25 (br s, 1H), 6.41 (d, J =
15.82 Hz, 1H), 6.91 (ddd, J = 8.05, 2.49, 1.17 Hz, 1H), 7.02−
7.10 (m, 2H), 7.21−7.28 (m, 1H), 7.65 (d, J = 16.11 Hz, 1H).
HRMS (ESI): calcd for [C10H10O3 + H]
+, 179.0703; found,
179.0710. The suspension of methyl 3-(3-hydroxyphenyl)-
acrylate 47 (1.00 g, 5.612 mmol) and 10% Pd/C in ethyl
acetate was stirred at room temperature under H2 for 2 h. After
ﬁltration through Celite, the ﬁltrate was evaporated and the
crude intermediate methyl 3-(3-hydroxyphenyl)propanoate 48
was obtained (0.91 g, 90%). According to a literature
procedure,51 the suspension of methyl 3-(3-hydroxyphenyl)-
propanoate 48 (0.58 g, 3.2 mmol), phenylboronic acid (1.17 g,
9.6 mmol), Cu(OAc)2 (1.16 g, 6.4 mmol), molecular sieves
(0.60 g), and pyridine (0.77 mL, 9.6 mmol) in 1,2-
dichloroethane (10 mL) yielded compound 51 as a light
yellow gel (0.41 g, 50%). 1H NMR (300 MHz, CDCl3): δ
2.58−2.65 (m, 2H), 2.89−2.96 (m, 2H), 3.66 (s, 3H), 6.82−
6.88 (m, 2H), 6.91−6.96 (m, 1H), 6.97−7.03 (m, 2H), 7.06−
7.13 (m, 1H), 7.20−7.28 (m, 1H), 7.29−7.38 (m, 2H). HRMS
(ESI): calcd for [C16H16O3 + H]
+, 257.1172; found, 257.1178.
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3-(3-Phenoxyphenyl)propanal (52). Following the proce-
dure described for compound 50, methyl 3-(3-phenoxyphenyl)-
propanoate 51 (0.40 g, 1.57 mmol) was ﬁrst reduced by LiAlH4
(148.6 mg, 3.91 mmol) in dry THF (10 mL) to oﬀer
intermediate 3-(3-phenoxyphenyl)propan-1-ol, which was
dissolved with dry CH2Cl2 (3 mL). Dess−Martin reagent
(0.80 g, 1.88 mmol) was added to the reaction mixture at 0 °C
under argon. The desired compound 52 (147.7 mg, 45%) was
obtained as a colorless oil. 1H NMR (300 MHz, CDCl3): δ
2.72−2.81 (m, 2H), 2.73−2.80 (m, 2H), 2.90−2.98 (m, 2H),
6.81−6.87 (m, 2H), 6.90−6.96 (m, 1H), 6.97−7.03 (m, 2H),
7.11 (tt, J = 7.32, 1.17 Hz, 1H), 7.21−7.28 (m, 1H), 7.31−7.38
(m, 2H), 9.81 (t, J = 1.32 Hz, 1H). HRMS (ESI): calcd for
[C15H14O2 + H]
+, 227.1067; found, 227.1065.
2-Methyl-4-phenoxyquinoline (54). According to a modi-
ﬁed literature procedure,52 the suspension of 4-chloro-2-
methylquinoline 53 (0.53 g, 3 mmol), phenol (0.85 g, 9
mmol), Cs2CO3 (2.93 g, 9 mmol), N,N-dimethylglycine
hydrochloride (125.6 mg, 0.9 mmol), and CuI (57.1 mg, 0.3
mmol) in dry 1,4-dioxane (5 mL) under air with a drying tube
was stirred at 90 °C for 24 h. After cooling to room
temperature, the reaction mixture was diluted with CH2Cl2 (20
mL) and ﬁltered. The ﬁltrate was washed with CH2Cl2 (100
mL), and the combined organic layer was evaporated; the
residue was puriﬁed with column chromatography (100%
toluene−90% toluene/ethyl acetate) to yield compound 54 as a
white solid (158.8 mg, 23%). 1H NMR (300 MHz, CDCl3): δ
2.61 (s, 3H), 6.44 (s, 1H), 7.17−7.22 (m, 2H), 7.28−7.35 (m,
1H), 7.46−7.56 (m, 3H), 7.74 (ddd, J = 8.57, 6.96, 1.46 Hz,
1H), 8.06 (d, J = 7.91 Hz, 1H), 8.31 (dd, J = 8.35, 1.03 Hz,
1H). HRMS (ESI): calcd for [C16H13NO + H]
+, 236.1070;
found, 236.1079.
4-Phenoxyquinoline-2-carbaldehyde (55). According to a
literature procedure,49 2-methyl-4-phenoxyquinoline 54 (100.0
mg, 0.43 mmol) and SeO2 (94.3 mg, 0.85 mmol) were
dissolved with 1,4-dioxane (6 mL). The suspension was heated
at 80 °C for 2 h. After cooling to room temperature, the
reaction mixture was ﬁltered through Celite. The ﬁltrate was
evaporated and puriﬁed with column chromatography (100%
hexane−10% ethyl acetate/hexane) to oﬀer compound 55 as a
white solid (80.0 mg, 75%). 1H NMR (300 MHz, CDCl3): δ
7.16 (s, 1H), 7.17−7.23 (m, 2H), 7.35 (tt, J = 7.47, 1.17 Hz,
1H), 7.47−7.54 (m, 2H), 7.73 (ddd, J = 8.27, 6.96, 1.17 Hz,
1H), 7.87 (ddd, J = 8.42, 6.81, 1.46 Hz, 1H), 8.25 (d, J = 8.49
Hz, 1H), 8.46 (dd, J = 8.35, 1.32 Hz, 1H), 10.11 (s, 1H).
HRMS (ESI): calcd for [C16H12NO2 + H]
+, 250.0863; found,
250.0870.
4-(3-Chlorophenoxy)quinoline-2-carbaldehyde (57). Fol-
lowing the Ullmann coupling procedure described for
compound 54, the suspension of 4-chloro-2-methylquinoline
53 (0.44 g, 2.5 mmol), 3-chlorophenol (0.96 g, 7.5 mmol),
Cs2CO3 (2.44 g, 7.5 mmol), N,N-dimethylglycine hydro-
chloride (104.7 mg, 0.75 mmol), and CuI (47.6 mg, 0.25
mmol) in dry 1,4-dioxane (8 mL) under air with a drying tube
yielded 4-(3-chlorophenoxy)-2-methylquinoline 56 (210.0 mg,
31%). According to a modiﬁed literature procedure,49 the
suspension of compound 56 (210.0 mg, 0.7 mmol) and SeO2
(150.5 mg, 1.4 mmol) in 1,4-dioxane (8 mL) was heated at 80
°C for 1.5 h. After cooling to room temperature, the reaction
mixture was ﬁltered through Celite. The ﬁltrate was evaporated
and puriﬁed with column chromatography (100% hexane−10%
ethyl acetate/hexane in a linear gradient elution) to oﬀer
compound 57 as a white solid (181.0 mg, 91%). 1H NMR (300
MHz, CDCl3): δ 7.11 (ddd, J = 8.20, 2.34, 1.17 Hz, 1H), 7.19
(s, 1H), 7.23 (t, J = 2.20 Hz, 1H), 7.34 (ddd, J = 8.13, 1.98,
1.03 Hz, 1H), 7.44 (t, J = 8.05 Hz, 1H), 7.72−7.78 (m, 1H),
7.89 (ddd, J = 8.49, 6.88, 1.61 Hz, 1H), 8.29 (dd, J = 8.35, 1.03
Hz, 1H), 8.38−8.43 (m, 1H), 10.15 (s, 1H). HRMS (ESI):
calcd for [C16H10ClNO2 + H]
+, 284.0473; found, 284.0479.
7-Chloro-4-phenoxyquinoline-2-carbaldehyde (60). Fol-
lowing the Ullmann coupling procedure described with
compound 54, the suspension of 4,7-dichloro-2-methylquino-
line 58 (0.53 g, 2.5 mmol), phenol (0.71 g, 7.5 mmol), Cs2CO3
(2.44 g, 7.5 mmol), N,N-dimethylglycine hydrochloride (104.7
mg, 0.75 mmol), and CuI (47.6 mg, 0.25 mmol) in dry 1,4-
dioxane (5 mL) under air with a drying tube yielded 4-(3-
chlorophenoxy)-2-methylquinoline as a yellow solid, 7-chloro-
2-methyl-4-phenoxyquinoline 59 (156.0 mg, 23%). 1H NMR
(300 MHz, CDCl3): δ 2.58 (s, 3H), 6.41 (s, 1H), 7.15−7.18
(m, 1H), 7.20 (q, J = 1.86 Hz, 1H), 7.29−7.36 (m, 1H), 7.45−
7.53 (m, 3H), 8.03 (d, J = 1.76 Hz, 1H), 8.24 (d, J = 9.08 Hz,
1H). HRMS (ESI): calcd for [C16H12ClNO + H]
+, 270.0680;
found, 270.0615. According to a literature procedure,49 the
suspension of compound 59 (146.0 mg, 0.54 mmol) and SeO2
(120.1 mg, 1.08 mmol) in 1,4-dioxane (5 mL) was heated at 80
°C for 2 h. After cooling to room temperature, the reaction
mixture was ﬁltered through Celite. The ﬁltrate was evaporated
and puriﬁed with column chromatography (100% hexane−10%
ethyl acetate/hexane in a linear gradient elution) to oﬀer
compound 60 as a white solid (138.2 mg, 90%). 1H NMR (300
MHz, CDCl3): δ 7.13 (s, 1H), 7.16−7.22 (m, 2H), 7.32−7.39
(m, 1H), 7.47−7.55 (m, 2H), 7.67 (dd, J = 9.08, 2.05 Hz, 1H),
8.24 (d, J = 2.05 Hz, 1H), 8.39 (d, J = 8.79 Hz, 1H), 10.07 (s,
1H). 13C NMR (75 MHz, CDCl3): δ 99.99, 121.11 (2C),
121.36, 123.66, 126.42, 128.81, 129.54, 130.64 (2C), 137.29,
149.76, 153.50, 154.66, 163.24, 193.16. HRMS (ESI): calcd for
[C16H10ClNO2 + H]
+, 284.0473; found, 284.0468.
tert-Butyl 4-((Methylsulfonyl)oxy)piperidine-1-carboxylate
(61). According to a modiﬁed literature procedure,53 a solution
of tert-butyl 4-hydroxypiperidine-1-carboxylate (10.06 g, 50
mmol) and triethylamine (10.81 mL, 77.5 mmol) in CH2Cl2
(200 mL) at 0−5 °C was treated with methanesulfonyl chloride
(4.64 mL, 60 mmol). After 2 h, the reaction mixture was diluted
with CH2Cl2 (100 mL) and washed with saturated NaHCO3
(100 mL) and brine (100 mL) sequentially, followed by drying
over Na2SO4. After evaporation, the residue was puriﬁed by
column chromatography (95% CH2Cl2/MeOH) to oﬀer
compound 61 as a white solid (11.31 g, 81%). 1H NMR
(300 MHz, CDCl3): δ 1.46 (s, 9H), 1.74−1.89 (m, 2H), 1.89−
2.04 (m, 2H), 3.04 (s, 3H), 3.30 (m, 2H), 3.71 (m, 2H), 4.88
(tt, J = 7.76, 3.81 Hz, 1H). HRMS (ESI): calcd for
[C11H21NO5S + H]
+, 280.1213; found, 280.1210.
3-((Benzyloxy)methyl)-5-methylpyrimidine-2,4(1H,3H)-
dione (62). According to a literature procedure,54 62 was
obtained as a white solid. 1H NMR (300 MHz, CDCl3): δ 1.78
(d, J = 1.17 Hz, 3H), 4.58 (s, 2H), 5.31 (s, 2H), 7.23−7.37 (m,
6H), 10.94 (br s, 1H). HRMS (ESI): calcd for [C13H14N2O3 +
H]+, 247.1077; found, 247.1080.
3-((Benzyloxy)methyl)-5-methyl-1-(piperidin-4-yl)-
pyrimidine-2,4(1H,3H)-dione (63). According to a literature
procedure,24 a suspension of 3-((benzyloxy)methyl)-5-methyl-
pyrimidine-2,4(1H,3H)-dione (62, 0.29 g, 1.18 mmol), tert-
butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate (61,
0.33 g, 1.18 mmol), and potassium carbonate (0.32 g, 2.31
mmol) in dry DMF (5 mL) was stirred at 80 °C for 36 h under
argon. Additional 61 (0.33 g, 1.18 mmol) and potassium
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carbonate (0.17 g, 1.23 mmol) were added to the reaction
mixture, and the mixture was stirred at 80 °C for 24 h.
Additional 61 (0.33 g, 1.18 mmol) and potassium carbonate
(0.16 g, 1.16 mmol) were added, and the mixture was stirred at
80 °C for another 24 h. After cooling to room temperature, the
reaction mixture was diluted with CH2Cl2 (50 mL), following
by washing with water (50 mL) and brine (50 mL). The
organic layer was dried over Na2SO4. After evaporation, the
residue was puriﬁed by column chromatography (50% hexane/
ethyl acetate) to give the intermediate, which was dissolved
with CH2Cl2 (10 mL), and TFA (1 mL) was added to the
solution. The reaction mixture was stirred at room temperature
for 3 h, followed by evaporation in vacuo. The residue was
dissolved in a saturated NaHCO3 solution (15 mL) and
extracted with CH2Cl2 (30 mL × 3). The combined organic
layers were washed with brine (50 mL × 2) and dried over
sodium sulfate. The water layer can be re-extracted again if the
product is found by TLC. After evaporation, the residue was
puriﬁed by column chromatography (0.1% Et3N/4% MeOH/
CH2Cl2) to aﬀord compound 63 as a colorless gel (259.8 mg,
67%). 1H NMR (300 MHz, CDCl3): δ 1.58−1.73 (m, 2H),
1.80−1.90 (m, 2H), 1.92 (d, J = 1.17 Hz, 3H), 2.76 (td, J =
12.16, 2.34 Hz, 2H), 3.15−3.28 (m, 2H), 4.54−4.68 (m, 1H),
4.71 (s, 2H), 5.51 (s, 2H), 7.03 (d, J = 1.17 Hz, 1H), 7.23−7.39
(m, 5H). 13C NMR (75 MHz, CDCl3): δ 13.31, 31.19 (2C),
45.57 (2C), 52.97, 70.89, 72.28, 110.27, 127.65 (2C), 128.27
(3C), 134.93, 138.06, 151.50, 163.23. HRMS (ESI): calcd for
[C18H23N3O3 + H]
+, 330.1812; found, 330.1810.
3-((Benzyloxy)methyl)-5-methyl-1-(piperidin-4-ylmethyl)-
pyrimidine-2,4(1H,3H)-dione (65). Following a literature
procedure,55 to the solution of tert-butyl 4-(hydroxymethyl)-
piperidine-1-carboxylate (1.08g, 5.00 mmol) in CH2Cl2 (15
mL) were added triethylamine (0.70 mL, 5.00 mmol), 4-DMAP
(190.9 mg, 1.56 mmol), and methanesulfonyl chloride (0.44
mL, 5.63 mmol) to yield the mesylate 64 (1.43 g, 97%).
According to a modiﬁed procedure,24 the mixture of 62 (0.42 g,
1.20 mmol), compound 64 (0.53 g, 1.8 mmol), and potassium
carbonate (0.33 g, 2.4 mmol) in dry DMF (10 mL) was stirred
at 80 °C overnight to yield the N-Boc-protected intermediate,
which was deprotected with 10% TFA/CH2Cl2 (20 mL) to
yield compound 65 as a colorless gel (0.41 g, 77%). 1H NMR
(300 MHz, CDCl3): δ 1.21 (qd, J = 12.20, 4.10 Hz, 2H), 1.65
(d, J = 12.30 Hz, 2H), 1.84−1.97 (m, 4H), 2.42 (br s, 1H), 2.59
(td, J = 12.23, 2.49 Hz, 2H), 3.07−3.16 (m, 2H), 3.56 (d, J =
7.03 Hz, 2H), 4.71 (s, 2H), 5.51 (s, 2H), 6.89 (d, J = 1.17 Hz,
1H), 7.21−7.40 (m, 5H). 13C NMR (75 MHz, CDCl3): δ
13.01, 30.21 (2C), 35.54, 45.69 (2C), 55.40, 70.72, 72.26,
109.56, 127.63 (3C), 128.26 (2C), 138.04, 139.75, 151.63,
163.76. HRMS (ESI): calcd for [C19H25N3O3 + H]
+, 344.1969;
found, 344.1970.
tert-Butyl 3-((Methylsulfonyl)oxy)azetidine-1-carboxylate
(66). According to a modiﬁed literature procedure,53 a solution
of tert-butyl 3-hydroxyazetidine-1-carboxylate (2.60 g, 15
mmol) and triethylamine (3.24 mL, 23.25 mmol) in CH2Cl2
(75 mL) at 0−5 °C was treated with methanesulfonyl chloride
(1.39 mL, 18 mmol). After 1 h, the reaction mixture was diluted
with CH2Cl2 (75 mL) and washed with saturated NaHCO3 (50
mL) and brine (50 mL) sequentially, followed by drying over
Na2SO4. After evaporation, the residue was puriﬁed by column
chromatography (95% CH2Cl2/MeOH) to oﬀer compound 66
as a white solid (3.58 g, 95%). 1H NMR (300 MHz, CDCl3): δ
1.44 (s, 9H), 3.06 (s, 3H), 4.06−4.13 (m, 2H), 4.24−4.31 (m,
2H), 5.20 (tt, J = 6.66, 4.17 Hz, 1H). HRMS (ESI): calcd for
[C9H17NO5S + H]
+, 251.0827; found, 251.0824.
1-(Azetidin-3-yl)-3-((benzyloxy)methyl)-5-methylpyrimi-
dine-2,4(1H,3H)-dione (67). According to a modiﬁed literature
procedure,24 the reaction mixture of 66 (0.75 g, 3 mmol), 62
(0.49 g, 2 mmol), and potassium carbonate (0.55 g, 4 mmol) in
dry DMF (10 mL) was stirred at 80 °C for 24 h. 66 (1 equiv)
and potassium carbonate (1 equiv) were added to the reaction
mixture. After 24 h, the reaction mixture was worked up as
described in the literature to oﬀer compound 67 as a colorless
gel (0.26 g, 44%). 1H NMR (300 MHz, CDCl3): δ 1.98 (d, J =
1.17 Hz, 3H), 2.27 (br s, 1H), 3.67−3.77 (m, 2H), 4.12 (t, J =
8.49 Hz, 2H), 4.70 (s, 2H), 5.24−5.36 (m, 1H), 5.50 (s, 2H),
7.21−7.39 (m, 5H), 7.51 (d, J = 1.17 Hz, 1H). 13C NMR (75
MHz, CDCl3): δ 13.23, 50.86, 53.14 (2C), 70.75, 72.26, 110.92,
127.65 (3C), 128.26 (2C), 135.67, 138.00, 151.31, 163.37.
HRMS (ESI): calcd for [C16H19N3O3 + H]
+, 302.1499; found,
302.1501.
3-((Benzyloxy)methyl)-5-methyl-1-(2-(methylamino)-
ethyl)pyrimidine-2,4(1H,3H)-dione (69). According to a
literature procedure,56 to the mixture of 2-(methylamino)-
ethan-1-ol 68 (4.13 g, 55 mmol) and triethylamine (9.6 mL, 69
mmol) in CH2Cl2 (100 mL) was added (Boc)2O (10 g, 45.82
mmol) at 0 °C. The mixture was stirred at room temperature
for 2 h and quenched by 1 M HCl (200 mL). The organic layer
was washed with 1 M HCl (100 mL) and brine (100 mL)
sequentially. After the residue was dried over Na2SO4, the
organic solvent was evaporated to oﬀer the intermediate tert-
butyl (2-hydroxyethyl)(methyl)carbamate as a colorless gel
(8.67 g, 90%). To the solution of tert-butyl (2-hydroxyethyl)-
(methyl)carbamate (1.4 g, 8 mmol) in CH2Cl2 (20 mL) were
added triethylamine (1.46 mL, 10.4 mmol) and methanesul-
fonyl chloride (0.66 mL, 8.4 mmol) at 0 °C. The reaction
mixture was stirred at 0 °C for 1 h and quenched with 1 M HCl
(20 mL). The organic layer was washed with 1 M HCl (20 mL
× 2) and brine (40 mL). After the residue was dried over
Na2SO4, the organic layer was evaporated to oﬀer the crude
intermediate 2-((tert-butoxycarbonyl)(methyl)amino)-
ethylmethanesulfonate, which was unstable and used for next
step directly. According to a modiﬁed procedure,24 the reaction
mixture of the mesylate (1.01 g, 4 mmol), 3-((benzyloxy)-
methyl)-5-methylpyrimidine-2,4(1H,3H)-dione 62 (0.49 g, 2
mmol), and potassium carbonate (0.55 g, 4 mmol) in dry DMF
(5 mL) was stirred at 80 °C for 24 h. Mesylate (1.01 g, 4
mmol) was added to the reaction mixture, which was stirred at
80 °C for 24 h to oﬀer the N-Boc-protected intermediate. The
intermediate was dissolved with 10% TFA/DCM (20 mL) at
room temperature to oﬀer the desired product 69 as a colorless
oil (140.0 mg, 23%). 1H NMR (300 MHz, CDCl3): δ 1.54 (br
s, 1H), 1.92 (d, J = 1.17 Hz, 3H), 2.45 (s, 3H), 2.87 (t, J = 6.00
Hz, 2H), 3.80 (t, J = 6.00 Hz, 2H), 4.71 (s, 2H), 5.51 (s, 2H),
7.01 (q, J = 1.17 Hz, 1H), 7.22−7.40 (m, 5H). 13C NMR (75
MHz, CDCl3): δ 13.04, 36.30, 49.08, 50.16, 70.68, 72.23,
109.59, 127.58 (2C), 127.68 (2C), 128.26, 138.10, 139.77,
151.69, 163.85. HRMS (ESI): calcd for [C16H21N3O3 + H]
+,
304.1656; found, 304.1634.
3-((Benzyloxy)methyl)-5-methyl-1-(3-(methylamino)-
propyl)pyrimidine-2,4(1H,3H)-dione (71). Following the pro-
cedure described for compound 69, 3-(methylamino)propan-1-
ol 70 (5.05g, 56.7 mmol) was treated with (Boc)2O, followed
by the preparation of mesylate. The alkylation between the
mesylate (1.07 g, 4 mmol), compound 62 (0.49 g, 2 mmol),
and potassium carbonate (0.55 g, 4 mmol) in dry DMF (5 mL)
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oﬀered compound 71 as a colorless oil (440 mg, 69%). 1H
NMR (300 MHz, CDCl3): δ 1.88−1.96 (m, 5H), 2.46 (s, 3H),
2.65 (t, J = 6.74 Hz, 2H), 2.81 (br s, 1H), 3.82 (t, J = 6.88 Hz,
2H), 4.71 (s, 2H), 5.51 (s, 2H), 7.04 (q, J = 1.17 Hz, 1H),
7.21−7.40 (m, 5H). 13C NMR (75 MHz, CDCl3): δ 12.99,
28.30, 35.87, 46.99, 47.87, 70.68, 72.23, 109.95, 127.61 (2C),
127.65 (2C), 128.27, 138.04, 139.45, 151.69, 163.79. HRMS
(ESI): calcd for [C17H13N3O3 + H]
+, 318.1812; found,
318.1810.
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red uptake; PaβN, phenylalanine-arginine β-naphthylamide;
RSCC, real-space correlation coeﬃcient; RLU, relative light
units; TCEP, tris(2-carboxyethyl)-phosphine; TLS, translation-
libration-screw; TMPK, thymidylate kinase; XDR-TB, exten-
sively drug-resistant TB
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